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Abstract
Staphylococcus aureus is a human pathogen with the potential to cause lifethreatening diseases, but it can also be found as a commensal in up to 50% of the
population. Its main reservoir is located in the nostrils, where macrophages are the
principal mucosal APC and elicit a predominantly IL-10 response. Induction of IL-10
requires phosphoinositide 3-kinase activity, upon stimulation with S. aureus ligands
through toll-like receptor 2 binding. It is hypothesized that IL-10 production by
macrophages in the nasal mucosa allows S. aureus to persist in this niche as a
commensal. To test this hypothesis, a cohort of S. aureus nasal carriers and non-carriers
was developed and cytokine responses were compared between these groups. The data
suggest that carriers may be producing more IL-10 than non-carriers, while TNF-α
production remained unchanged, in response to heat-killed S. aureus. This differential IL10 production could be a key factor behind S. aureus commensalism.
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Introduction
Staplylococcus aureus (S. aureus) is a Gram positive bacterium known to cause a

wide range of clinically important infections including sinusitis, pneumonia and toxic
shock syndrome (TSS).1 S. aureus has been reported to be the most common clinical
isolate from skin and respiratory tract infections, as well as the second most common
cause of nosocomial infections, leading to over 500,000 hospitalizations per year in the
United States of America (USA).2 Albeit being an important health threat, S. aureus is
also found as commensal bacteria in 20-50% of the population, primarily in the nostrils.
It has been shown that permanent nasal carriers of S. aureus have a higher risk of
developing an infection by these bacteria than non-carriers, and several studies have
proposed different mechanisms to explain the persistence of S. aureus in the human body
without causing disease.3
Previous research conducted by the laboratory of Dr. Madrenas demonstrated that
antigen presenting cells (APCs) produce the immunomodulatory cytokine interleukin
(IL)-10, upon binding of Toll-like receptor (TLR) 2 by ligands derived from the
staphylococcal cell wall. These staphylococcal ligands are peptidoglycan (PGN)embedded lipopeptides and glycopolymers, such as cell wall-derived teichoic acid and
lipoteichoic acid (LTA).4 Both PGN and LTA elicit an IL-10 response from monocytederived macrophages and dendritic cells,5 two different types of APCs.6 The TLR2mediated IL-10 response is dependent on phosphoinositide 3-kinase (PI3K) activity.5
However macrophages and dendritic cells respond differently to PGN and LTA with
respect to their production of the p40 subunit of IL-12 and IL-23 (IL-12/23p40), which
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are pro-inflammatory helper T cells (TH)1/TH17 cytokines. Dendritic cells produce IL12/23p40 in response to PGN and LTA, but PI3K activity is not required in this response.
In contrast, macrophages produce IL-12p40 upon PGN stimulation, when PI3K activity is
inhibited. Thus, staphylococcal TLR2 ligands have differential effects depending on what
APC they encounter, and these differential responses might depend on the role of PI3K
downstream of ligand-activated TLR2 present on the different APCs.5
Macrophages are the predominant APC in the upper respiratory tract, including
the nostrils6, and they do not display a pro-inflammatory IL-12/23p40 response to PGN
or LTA, but rather a modulatory IL-10 response.5 Dendritic cells are the predominant
APC in the skin6 and they produce IL-12/23p40 in response to the same S. aureus
ligands.5 Based on these results, it was proposed that the different outcomes in response
to S. aureus, ranging from commensalism to lethal disease, depend on where the infection
takes place and which APC the bacteria encounters at the location, and the differential
activation of the PI3K/Akt, or PI3K/protein kinase B (PKB), pathway. From this, it can
be inferred that for subjects who carry S. aureus in their nostrils and remain healthy,
bacterial ligands interacting with macrophages trigger a predominantly IL-10-mediated
anti-inflammatory response that allows the bacteria to remain in this niche. The purpose
of the research presented in this thesis was to test the hypothesis that the antiinflammatory effects of IL-10, produced in response to TLR2 S. aureus ligands,
provides the basis for the persistence of this bacteria in the human nostrils as a
commensal. The following is a review of S.aureus as a health threat and as a commensal
that includes the different aspects of the immune system involved in S. aureus
recognition and infection control.
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1.1 Staphylococcus aureus (S. aureus)
1.1.1

General characteristics of S. aureus
S. aureus is a Gram positive, facultative anaerobic bacterium7 that belongs to the

Micrococcaceae family, Staphylococcus genus. It is distinguished from other
staphylococcal species because of its positive results for coagulase, mannitol
fermentation and deoxyribonuclease tests, as well as for the golden color of its colonies.1
Its genome ranges from 2.8 to 2.9 Mb8 distributed between a circular chromosome,
prophages, transposons and plasmids, as well as extrachromosomal elements. Compared
to other pathogenic bacterial species, S. aureus is highly clonal, and under suitable
clinical conditions, every strain has the potential of becoming highly pathogenic.
However, some clones are more virulent than others.3
The cell wall of S. aureus is composed mainly of PGN, consisting of alternating
polysaccharide subunits of N-acetylglucosamine and N-acetylmuramic acid with 1,4-β
linkages.1 These PGN chains are cross-linked by tetrapeptide chains bound to Nacetylmuramic acid and by a pentaglycine bridge specific to S. aureus. The
glycopolymers ribitol teichoic acids and LTA are also major components of the cell wall.
Ribitol teichoic acids are covalently bound to PGN, and LTA is a glycerol phosphate
polymer linked to a glycolypid terminus anchored in the cytoplasmic membrane. In the
PGN layer there are also other proteins and lipoproteins covalently and non-covalently
linked to PGN, and most strains also have a polysaccharide capsule.9 On the surface of S.
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aureus there are also several proteins called microbial-surface components recognizing
adhesive matrix molecules (MSCRAMM).10 These proteins bind to extracellular-matrix
molecules in host tissues and therefore, play a critical role in S. aureus colonization and
infection.1
During the processes of colonization and infection, S. aureus also deploys
different mechanisms to evade the immune system. Through the expression of surface
proteins, such as protein A, or by secreting factors, such as α-toxin, it has developed
strategies to avoid phagocytosis, inhibit neutrophil chemotaxis, and kill leukocytes.9 One
type of toxin that S. aureus secretes are superantigens, which are associated with severe
clinical consequences.11

1.1.2

S. aureus pathogenicity
Infection by S. aureus can lead to a wide range of clinical conditions, from

relatively mild skin infections such as folliculitis and furunculosis to severe diseases such
as endocarditis, osteomyelitis or sepsis. Infection with S. aureus is treated normally with
antibiotics12, but this type of treatment has now become more challenging due to the
appearance of methicillin-resistant (MRSA) strains. The antibiotic of last resort for the
treatment of MRSA is usually vancomycin, but S. aureus strains that are resistant to this
antibiotic have also been reported.13 S. aureus infections lead to almost 500,000
hospitalizations and almost 30,000 deaths per year in the USA, of which, more than half
are attributed to MRSA. Length of hospital stay, cost and death rate of a patient with a S.
aureus-related clinical condition is double that for a typical hospitalized patient. S. aureus
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is also the second most common cause of nosocomial infections , and it was estimated
that overall it costs $9 billion per year in the USA. 2, 14, 15
One of the most severe diseases that can be caused by S. aureus is toxic shock
syndrome (TSS), which is triggered by superantigens.11 Superantigens are pyrogenic
exotoxins secreted by S. aureus that bind to sites on the variable region of the β chain
(Vβ) of the T cell receptor (TCR) and to the α and/or β chain of the majorhistocompatibility complex class II (MHC-II) molecules.11 When a superantigen binds to
these two molecules, it causes T cell activation, independently of the peptide antigen
being presented by the APC’s MHC-II molecules. S. aureus produces several different
superantigens, but not all strains produce all or the same superantigens.11 Each
superantigen also has different Vβ specificities; i.e. superantigens activate T cells in an
antigen-independent and Vβ-specific manner.16 This type of T cell activation is not
clonal, as one superantigen can activate up to 20% of all the T cells in the human body,
generating a cytokine storm that leads to TSS.16

1.1.3

S. aureus commensalism
Despite S. aureus being such a significant health threat, it also behaves as a

commensal in the human body.17 This is the reason why it fits into the definition of a
pathobiont, which is any microbe that in spite of retaining potential for pathogenicity, is
also able to coexist with a healthy host. This definition separates pathobionts from
opportunistic microorganisms, which would not interact with a healthy host unless their
defenses became compromised.18 S. aureus is present permanently in 20% (12-30%) of

6

the general population, 30% (16-70%) carry it transiently and approximately 50% (1669%) do not carry the bacteria.3 The standards which define these three different groups
within the population (permanent carriers, transient carriers and non-carriers) vary
between different studies, ranging from two nasal swabs in a week interval, to at least
seven nasal swabs.3 Some of them follow volunteers for one year, and some of them also
take into consideration the bacterial burden in each swab, since the bacterial load is
higher in permanent than in transient carriers.3 As a consequence, depending on the
requirements of each study, a transient carrier in one study can be classified as a transient
carrier, permanent carrier, or non-carrier in another study. The more times a given subject
is tested for S. aureus nasal carriage, the higher probability they will be found to be a
transient carrier. Not only do S. aureus transient carriers have a smaller bacterial burden
compared to permanent carriers, but they also carry different strains over time, as
opposed to permanent carriers, who only carry one strain.3 Furthermore, if permanent
carriers are inoculated with S. aureus strains different to their own, these different newly
acquired strains are cleared, with only the original strain persisting.19
The main reservoir of S. aureus in the body is the vestibulum nasi, in the anterior
nares.3 The epithelial inner wall of a nostril is fully keratinised, which is very important
for bacterial binding.20 S. aureus can also be found in other parts of the body such as
perineum, pharynx, hands, and skin of the abdomen or chest. The main transmitting
vector of S. aureus to the nose is via the hands.21 Carriage rates are highest during
childhood (more than 70% of newborns have at least one positive nasal culture22), but
then carriage frequency decreases with age.23-25 Ethnicity and gender also seem to play a
role, and as a population group, Caucasian males exhibit the highest rate of nasal
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carriage.12, 26, 27 Hospitalization and household contact (most mothers and their children
carry the same strain) have also been associated positively with nasal carriage rates.22, 28
Patients undergoing haemodialysis, with end stage liver disease, with HIV, with skin
disease, or with obesity have also been associated with having higher carriage rates.3
Most (80%) individuals who develop a skin infection are S. aureus nasal carriers.3 Using
bacteriophage typing as a technique to discriminate different strains of S. aureus,29 the
majority of the cases where nasal colonization and skin infection occurred together, the
infecting S. aureus was the same type as the colonizing.3 Moreover, S. aureus nasal
carriage increases the risk of nosocomial auto-infection after surgery, in patients
undergoing dialysis, or in an immunosuppressed state by a factor of three.30 Conversely,
non-carriers have fourfold increased mortality rate from S. aureus bacteraemia compared
to carriers.30 This can be explained by the high titers of neutralizing antibodies that are
found in carriers and are specific to the superantigens produced by their autologous
colonizing strain.31
A mechanism that would explain commensalism of superantigen-producing S.
aureus in the nostrils of healthy subjects was proposed by the Madrenas laboratory. It
was shown that PGN-embedded lipoproteins and glycopolymers bind TLR2 molecules on
APCs, and this triggers IL-10 production. Thus IL-10 acts to down-regulate the IL-2
production by T cells stimulated by superantigens,4 impairing development of TSS.

1.2

Pathogen recognition by the immune system

As described above, S. aureus deploys a wide range of strategies to colonize and
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infect the human body, as well as to avoid the immune system.9 However, in spite of all
these mechanisms, S. aureus presence or infection in the body does not go unnoticed.17
The immune system possesses different ways of detecting microorganisms, such as S.
aureus, and responding to their infection.6 The different pathogen sensing mechanisms of
the immune system, in addition to the array of responses that they trigger are described in
the following sections, with focus on the ones that affect S. aureus presence as a
pathogen or as a commensal.

1.2.1

The immune system
The immune system is responsible for preventing, detecting and clearing

infection.6 Immune mechanisms can be divided into two categories: innate mechanisms
and adaptive mechanisms.32 Innate immune mechanisms are the ones activated
immediately after an infection occurs and are not pathogen-specific. They are the first
defensive barrier and do not last very long, but are able to prevent or contain the
infectious agent if the load is not very high, through a variety of germline-encoded
receptors that discriminate between structures from the pathogen and the host, or infected
and normal cells.33 These responses generate inflammation in the site of infection and are
essential for the development of an adaptive immune response, which can be more
powerful because they are antigen-specific and thus target the specific pathogen more
precisely.6, 32 Adaptive immunity takes longer to be generated and it is triggered when an
infection eludes or overwhelms the innate mechanisms.6 An adaptive immune response is
initiated in the regional secondary lymphoid organ, in response to antigens presented by
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dendritic cells activated during the course of the innate immune response.32 Antigenspecific T cells and antibody-secreting B cells are generated by clonal expansion and
differentiation, and they will be the ones eventually driving the clearance of the
infection.34 Until these antigen-specific immune cells are fully active, the induced
responses of innate immunity such as the acute-phase responses and interferon
production continue to function.6

1.2.2

Role of innate immunity
During the course of a bacterial infection, the first thing that happens is tissue

injury, which leads to inflammation following establishment of a focus of infection.35
Inflammation is a consequence of the activation of different cell types, including
macrophages, that reside in the infected tissue by bacterial components that act as ligands
to different receptors on the immune cells.36 Activated macrophages secrete different
cytokines and chemokines that induce the activation of the vascular endothelium. This
means that the endothelial cells of nearby blood capillaries will become activated and upregulate their surface expression of P-selectin and E-selectin, which are involved in the
rolling phase of a leukocyte adhesion cascade, as well as intracellular adhesion molecule
1 (ICAM-1) and vascular cell adhesion protein 1 (VCAM-1), involved in the adhesion
phase.6 This process allows for inflammatory cells to enter the tissue and the
inflammatory response is maintained and reinforced. As monocytes enter the site of
infection, they mature into tissue macrophages and become activated as well.37 A second
crucial effect of infection is the activation of specialized antigen-presenting cells, the
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dendritic cells residing in host tissues. Dendritic cells take up antigen in the infected
tissues, and like macrophages, they are activated through innate immune receptors, such
as TLRs and nucleotide oligomerization domain (NOD) proteins, which respond to
common constituents of pathogens.6, 38 Activated dendritic cells increase their synthesis
of MHC–II and begin to express the co-stimulatory molecules B7.1 [cluster of
differentiation (CD) 80] and B7.2 (CD86) on their surface. Attracted by different
chemokines, they migrate from the site of infection, through the lymphoid system to
peripheral lymphoid tissues. There, they initiate the adaptive immune response by
activating naïve T cells.6

1.2.3

Pathogen recognition by the innate immune system
The presence of pathogens is detected by innate immune cells through pathogen

recognition receptors (PRRs). These molecules bind pathogen-associated molecular
patterns (PAMPs), which are repetitive structures common to many microorganisms.

6

PRRs can be classified according to where they are found: soluble in plasma, attached to
a cell membrane or in the cytoplasm.6, 33 Soluble in plasma PRRs can be further classified
into two different families of receptors. Members of the pentraxin family include Creactive protein (CRP) and serum amyloid protein (SAP), which are secreted by the liver
during the acute phase response at the early stages of infection. They bind
phosphorylcholine on bacterial surfaces, act as opsonins, and activate complement
through the classical pathway by binding C1q.39 Mannose-binding lectin (MBL) is
secreted by the liver with CRP and SAP, but MBL belongs to the collectin family.6 MBL
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binds to terminal mannose residues and associates with MBL-associated serine proteases
(MASP), which allows for this complex to activate the lectin pathway of complement by
cleaving C2 and C4 proteins.39 The collectin family contains both collagen-like and lectin
domains. Surfactant protein (SP)-A and SP-D are also members of this family and are
present in the fluid that bathes the epithelial surfaces of the lung. Binding of their ligands
on bacterial surfaces makes the microorganisms more susceptible to phagocytosis by
macrophages.6
Transmembrane PRRs can also be divided into several families. TLRs recognize a
wide range of PAMPs derived from bacterial cell wall, viral genomes, fungi and
protozoa. Ligand-binding of TLRs is sufficient to induce TH1, antibody and CD8+ T cell
responses.40 Dectin-1 recognizes fungal cell wall components and β-glucan, and its ligand
binding is sufficient to trigger TH17 and antibody responses.40 On the surface of
macrophages there is the macrophage mannose receptor, which is a calcium-dependent
lectin that recognizes certain sugars on the surface of bacteria and viruses. Its properties
are very similar to the ones of the MBL, but it can also function as a phagocytic
receptor.6 Scavenger receptors are also phagocytic receptors which recognize anionic
polymers and acetylated low-density lipoproteins.39 Additionally, the fMet-Leu-Phe
(fMLP) receptor is also present as a transmembrane molecule on macrophages and
neutrophils but does not act as a phagocytic receptor. Instead it acts as a chemotactic
receptor, which upon ligand binding drives neutrophil migration to the site of infection.6
Cytosolic PRRs can be divided into two classes depending on their mechanism of
action. The first one is formed by cytosolic PRRs that directly bind cytosolic PAMPs and
activate several signaling cascades. This family includes the nucleotide-binding

12

oligomerization domain containing (NOD)-like receptor (NLR) family members NOD1
and NOD2 and the retinoic acid-inducible gene I (RIG-I)-like helicases (RLHs).39 NOD1
and NOD2 bind to microbial components derived from bacterial PGN,41 and RIG-I
recognizes distinctive features of viral ribonucleic acid (RNA).33 Ligand binding of
NOD1 and NOD2 is sufficient to induce TH2 and antibody responses, and it also
potentiates TH1, TH2, TH17 and antibody responses previously initiated by TLR ligand
binding.39, 41 RIG-I ligand binding is sufficient to trigger CD8+ T cell responses.39 The
second class consists of members of the NLR family that are involved in the formation
and activation of the inflammasome, which controls the activation of caspase-1. Members
of this class belong to the NLR family and are Nacht domain-, LRR-, and PYDcontaining protein 3 (NALP3) and interferon (IFN)-stimulatory deoxyribonucleic acid
(DNA) (ISD) sensor. NALP3 is activated by potassium efflux, lipopolysaccharide (LPS)
plus adenine triphosphate (ATP), pore-forming toxins and bacterial secretion systems.
Ligand binding is required for T cell-dependent hypersensitivity.39 And lastly, ISD sensor
binds to viral RNA and ligand binding is sufficient to induce CD4+ T-cell and antibody
responses in hematopoietic cells, and to induce CD8+ T cell responses in nonhematopoietic cells.39

1.2.4

Toll-like receptors (TLRs)
TLRs are mainly expressed in APCs such as dendritic cells, macrophages and

activated B cells.42 There are ten different functional TLRs in human. Some of them are
localized in the cell membrane and others in the endosomal membrane. TLR1, TLR2,
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TLR4, TLR5, TLR6, TLR10 are localized in the plasma membrane and they recognize
ligands on the surface of pathogens.43 For example, TLR1/2 and TLR2/6 recognize
glycopolymers and lipopeptides embedded in PGN and TLR4 recognizes LPS. On the
other hand, TLR3, TLR7 and TLR9 are in the endosomal membrane and they recognize
different types of nucleic acids, such as single stranded (ss) RNA.43
TLRs are type I transmembrane proteins with a leucine-rich repeats ectodomain, a
transmembrane domain and an intracellular Toll-IL-1 receptor (TIR) domain, which
allows for recruitment of different adaptor molecules also with TIR domains by
homodimeric interactions.44 The different responses to the different PAMPs come from
the different combinations of adaptors that are recruited to each TLR and determine the
pathways that become activated.45 Overall, all the signal transduction pathways
downstream of TLR ligand binding can be divided into myeloid differentiation primaryresponse protein 88 (MyD88)-dependent and TIR domain-containing adaptor proteininducing IFNβ (TRIF)-dependent. MyD88 is used by all TLRs but TLR3, and leads to the
activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and
mitogen-activated protein (MAP) kinases, and cytokine production. TLR3 and TLR4 can
use TRIF mediated signalling pathways leading to the activation of NF-κB and interferon
regulatory factor 3 (IRF3) and the production of type I IFN and cytokines.43

1.2.5

TLR2 signalling
TLR2 recognizes PGN-embedded glycopolymers and lipopeptides,43 which are

found in the cell wall of Gram positive bacteria, such as S. aureus.1 Although most TLRs
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form homodimers, TLR2 signals through the heterodimers TLR1/2 and TLR2/6, which
recognize triacyl and diacyl lipopeptides, respectively.45 Upon TLR2 heterodimer-ligand
binding, the adaptor molecule MyD88 adaptor-like (Mal), or TIR domain containing
adaptor protein (TIRAP), binds to the cytoplasmic TIR domain of TLR2, and MyD88
binds to Mal.43 This protein complex recruits the protein kinases of the IL-1R-associated
kinase (IRAK) family and the E3 ligase TNFR-associated factor 6 (TRAF6), which
activates the protein kinase TGFβ-activated kinase 1 (TAK1). TAK1 phosphorylates the
inhibitor of nuclear factor kappa-B kinase subunit beta (IKKβ), leading to the activation
of NF-κB.42 Consequently, the transcription of a range of genes coding for proinflammatory cytokines (Fig. 1.1), including tumour necrosis factor (TNF), IL-6, IL-12,
pro-IL-1β and pro-IL-18 are activated.42, 46 TLR-induced activation of TAK1 also results
in phosphorylation of MAPKs, including p38 and extracellular signal-regulated kinase
(ERK) (Fig. 1.1).47 Phosphorylation of ERK promotes the transcription of the gene
encoding IL-23p19 and subsequent IL-23 synthesis. Phosphorylation of p38 activates
cyclic adenosine monophosphate (cAMP) response element-binding protein (CREB),
leading to IL-10 production. The various cytokines produced in response to bacteria
activate different subsets of T cells. IL-12 promotes TH1 cell differentiation, IL-10
induces regulatory T (Treg) cells and IL-1, IL-6, IL-18 and IL-23 promote TH17 cell
differentiation or proliferation.46
The immune response to S. aureus is initiated by PGN-embedded lipopeptides
binding to TLR1/2 and TLR2/6.43 MyD88 has been shown to interact with the TIR
domain of TLR1, TLR2 and TLR6, but in murine macrophages and dendritic cells, Mal
only interacts with TLR1 and TLR2.48 Also, Mal is not required for TLR2 heterodimers
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signalling at low concentrations of ligand, but it is required under conditions of high
concentration of ligands.48

Figure 1.1: TLR2 signalling cascade.
The adaptor proteins MyD88 and Mal are recruited to the TLR1/2 or TLR2/6
heterodimers upon ligand binding.

The adaptors bind to the heterodimers through
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homodimeric interactions between their TIR domains. Protein kinases from the IRAK
family are recruited to the complex, and they phosphorylate and activate TRAF6, an
ubiquitin ligase. TRAF6 activates TAK, which in turn activates the canonical NF-κB
pathway and the MAP kinase pathway, leading to activation of gene transcription.47

1.2.6

Signalling in the immune system: cytokines
Cytokines are small molecules released by immune cells and other cell types in

response to different stimuli.6 They induce responses by binding to specific receptors and
triggering signal transduction processes. Their effect can be autocrine, paracrine or
endocrine, and can be classified as: interleukins (IL), interferons (IFN), colonystimulating factors (CSF), tumor necrosis factors (TNF) and chemokines. IL are the most
numerous family. They are produced by leukocytes and other cell types such as epithelial
and endothelial cells.6, 49 Some of the most commonly studied are IL-1β, IL-2, IL-4, IL-6,
IL-8, IL-12 and IL-17. Secretion of some of these cytokines results in differentiation of
the producer cell into specific subtypes.50 IFN can be divided into INF-α and INF-β on
the one side, and IFN-γ on the other. The first two are produced by a wide variety of cells
in response to a viral infection,51 and the second is produced by CD4+ TH1 cells and its
main function is activation of macrophages.52 Three different CSF have been described:
granulocyte (G)-CSF, G macrophage (M)-CSF and M-CSF or CSF-1. They are produced
by innate and adaptive immune cells as well as other cell types and stimulate growth,
development and differentiation of different immune cell types.53 The TNF family
includes many members that are bound to the cell membrane and it is best represented by
TNF-α, which is produced by TH1 cells and macrophages.54 Finally, chemokines
comprise a subset of cytokines that act as chemoattractants of immune cells, inducing
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directed chemotaxis of nearby cells, and this way allowing them to reach places such as a
site of infection or a lymphoid organ.55
Some of the first cytokines released during an infection are produced by activated
macrophages whose PRRs have been stimulated, for instance TLR1/2 and TLR2/6
stimulated by staphylococcal PGN.56 They are the following: IL-1β, IL-6, IL-8 or CCL8,
IL-12 and TNF-α.6 IL-1β can also be produced by epithelial cells and activates vascular
endothelium, T cells and macrophages. IL-1β is involved in local tissue destruction and
in the increased access of effector cells to the site of infection.57 IL-6 is also produced by
endothelial cells and T cells. It leads to lymphocyte activation and to increase of antibody
production, since it activates B and T cell growth and differentiation.57,

58

IL-8 is a

chemotactic factor that recruits neutrophils, basophils and T cells, and activates
endothelial cells.55, 57 IL-12 is produced by dendritic cells and it activates natural killer
(NK) cells and drives the differentiation of CD4+ cells into TH1 cells.49 TNF-α activates
the vascular endothelium and increases vascular permeability, which leads to increased
entry of IgG, complement and immune cells. It also increases fluid drainage to lymph
nodes.34,

58

Together, IL-1β, IL-6 and TNF-α have many systemic effects, including:

fever, mobilization of metabolites and acute phase protein production.6, 58
When an immature dendritic cell in peripheral tissues is stimulated by TLR
ligands from pathogens such as S. aureus, they undergo maturation. This process
involves production of IL-6, IL-12, IL-18 and IFN-γ.6,

38

In addition, the chemokine

receptor CCR7 is up-regulated, which makes the dendritic cell sensitive to the
chemokines CCL19 and CCL21. These chemokines are produced by lymphoid tissues
and direct dendritic cell migration through the lymphatics to secondary lymphoid tissue.55
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They also provide maturation signals that result in up-regulation of the co-stimulatory
molecules B7.1 and B7.2, MHC-II and adhesion molecules.6, 38 IL-12 produced by T cells
and dendritic cells upon TLR ligation up-regulates the production of IFN-γ NK cells, and
directs the development of TH1 cells. IFN-γ stimulates macrophages and dendritic cells to
increase their secretion of IL-12 and to produce nitric oxide (NO), which kills the
infectious microbes.59
IL-10 is an anti-inflammatory cytokine and as such, it has a critical role in
preventing inflammatory and autoimmune pathologies.60,

61

IL-10 can act at different

stages of an immune response and it is expressed by many cells of both the innate and the
adaptive immune system, such as dendritic cells, macrophages, mast cells, NK cells,
eosinophils, neutrophils, the TH1, TH2 and TH17 cells subsets, Treg cells, CD8+ T cells and
B cells.60 IL-10 regulates growth and/or differentiation of B cells, NK cells, cytotoxic and
helper T cells, mast cells, granulocytes, dendritic cells, keratinocytes, and endothelial
cells.61 It also down-regulates the expression of co-stimulatory molecules in APCs60, but
up-regulates the expression of MHC-II in B cells.6 Although macrophages and dendritic
cells-secreted IL-10 has an autocrine inhibitory effect on cytokine release in
macrophages, it enhances the differentiation of IL-10 secreting Treg.61 In addition, it
inhibits TH1 cells and co-stimulates mast cell growth.6 IL-10 is produced upon TLR2
ligand binding in dendritic cells stimulated with Mycobacterium tuberculosis or with
lipopetides and the LcrV antigen of Yersinia pestis.60 IL-10 production by macrophages
stimulated with pneumococcal cell wall mainly depends on TLR2 as well.62 Macrophages
and dendritic cells have also been reported to produce IL-10 in response to TLR4 and
TLR9 ligands.63 Ligation of CD40 on dendritic cells and ligation of Fc receptors on
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macrophages, which were both also stimulated with TLR ligands, also enhances IL-10
production.60 ERK activation follows TLR ligation and leads to IL-10 production in
innate immune cells. Nevertheless, each cell type has different thresholds for activation
and this correlates with the differences in IL-10 production. Macrophages show the
highest ERK activation and also the highest IL-10 production, and dendritic cells have a
lower level of ERK activation and also produce lower levels of IL-10.60 In both cell
types, NF-κB controls IL-10 transcription, although in macrophages it is also under the
control of transcription factors CREB and SP1 among others.60

1.3

Signalling

through

phosphoinositide

3-kinase

(PI3K) in the immune system
Many surface receptors on immune cells require PI3K for signal transduction and
optimal response to the stimuli.64 Such is the case of IL-10 production upon TLR2
ligation: PI3K activity is required for IL-10 production by APCs upon stimulation with
staphylococcal PGN.5 IL-10 is an anti-inflammatory cytokine that down-regulates proinflammatory responses to pathogens60, such as S. aureus.4 Because PI3K activity is
required for this IL-10 production,5 the following sections will describe PI3K and its role
as a signal transducer in the immune system, and more specifically in the immune
responses to S. aureus.
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1.3.1

Characteristics and downstream signalling of PI3K
PI3K are a group of enzymes that phosphorylate lipid substrates.59 PI3Ks are

divided into three different classes according to their structure and their in vitro substrate
specificity. The structure common to all classes consists of a C2 domain, a helical domain
and a catalytic domain, and classes I and II also have a Ras-binding domain.64 Class I
PI3K is the most commonly studied, and it is the one that the rest of this introduction will
focus on, since it is the one involved in TLR2 signalling.65 Class I PI3K are formed by
two subunits, the regulatory and the catalytic, and they are classified into two different
subclasses depending on their regulatory subunit and the cell surface receptor that
activates them, class IA and IB.64 Class IA is formed by three different catalytic subunits
of 110 kDa approximately, p110α, p110β, and p110δ. These three catalytic subunits can
pair with any of the regulatory subunits from the IA class, which are p85α, p55α, and
p50α (all from the same gene), p85β, and p55γ.64,

66

Class IB is only formed by the

catalytic subunit p110γ, which can pair up with two different regulatory subunits, p101
and p87/p84.64 Traditionally class IA PI3Ks are known to be activated downstream of
receptors associated with protein tyrosine kinases, and class IB downstream of G-protein
coupled receptors.64, 66 Class I PI3K transfers a phosphate group to the 3’OH position of
the inositol ring of phosphoinositide 4, 5-biphosphate (PIP2) in the inner leaflet of the cell
membrane, going from PIP2 to phosphoinositide 3, 4, 5-triphosphate (PIP3). Classes II
and III are the least studied. They phosphorylate phosphoinositides and phosphoinositide
4-phosphate, and only one regulatory subunit has been described for class III.64 The
functions of classes II and III have been linked to signal transduction and vesicle
trafficking respectively.64
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PIP3 acts as a docking site for proteins with Pleckstrin Homology (PH) domains,
such as Akt, which becomes phosphorylated and activated by 3-phosphoinositide
dependent protein kinase-1 (PDK1), once it is closer to the inner cell membrane.66 The
recruitment of these proteins brings them closer to transmembrane receptors, as well as
other signal transduction factors recruited to the same site. This proximity favors
interactions among all these factors and facilitates the transduction of the initial signal to
other molecules and compartments of the cell.66 Activation of Akt leads to further
activation or inhibition of a plethora of other factors which are involved in many different
processes such as actin rearrangement, cell migration, cell cycle progression, protein
synthesis and cell growth (Fig. 1.2). 64, 66

1.3.2

PI3K activity in innate immune cells
From here on, class I PI3K will be referred as just PI3K. One of the downstream

effectors of the PI3K/Akt pathway is the mammalian target of rapamycin (mTOR).67
When Akt is active, it inhibits the tumour suppressor complex (TSC-1/2), which is an
inhibitor of the GTPase Ras homologue enriched in brain (Rheb). Rheb is essential for
mTOR-mediated phosphorylation and activation of S6 kinase-1 (S6K1). Phosphorylation
of S6K1 and phosphorylation and inactivation of the repressor of mRNA translation
eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) by mTOR promote protein
synthesis (Fig. 1.2).67, 68 The PI3K/Akt/mTOR signalling pathway has different effects on
innate immunity depending on the cell type. In mast cells it increases gastrointestinal
mast cell development, adhesion, migration, cytokine release and degranulation. In
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neutrophils it augments chemotaxis, phagocytosis, IL-8 production and respiratory
burst.67 In plasmacytoid dendritic cells it promotes type I IFNs via TLR7 and TLR9
stimulation. Finally, in monocytes, macrophages and myeloid dendritic cells, the
PI3K/Akt/mTOR pathway seems to be a positive regulator of IL-10 production and a
negative regulator of IL-12 and IL-23 production.69

1.3.3

PI3K activation upon TLR ligation
It is known that ligand binding to TLR2 (TLR1/2 and TLR2/6), TLR4, TLR5 and

TLR9 activates the PI3K signalling pathway and its downstream effects, such as gene
transcription.70 Inhibition of PI3K activity by wortmannin or LY294002 suppresses IL-10
production and augments IL-12 by impairing NF-κB activity upon TLR2 ligation.71 Also,
upon TLR2 ligation in human monocytes, inhibiting PI3K or mTOR leads to an increase
in IL-23 production and a decrease in IL-10 production.71 Stimulation of TLR3 and TLR4
in dendritic cells when PI3K is inhibited leads to an increase in NF-κB activation and in
IFN-β synthesis, and in macrophages to an increase in IL-12 and NO production.72,

73

PI3K is involved in different immune-related processes such as the degradation of the
cyclo-oxygenase 2 mRNA in alveolar macrophages and in C5a-mediated inhibition of IL12 production in monocytes upon TLR4 ligation. It is also required for IL-8 production
upon TLR5 ligation on epithelial cells.74 All these different observations suggest that
PI3K activity has a regulatory role in controlling immune responses initiated by TLR
ligation.65 Whether PI3K exerts positive or negative regulation, is likely dependent on the
cell type, on the TLR and on the different combinations of adaptor and effector molecules
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Figure 1.2: PI3K/Akt signalling pathway.
Generation of PIP3 by PI3K promotes actin rearrangement. PIP3 also recruits Akt
to the cell membrane, where it is activated and it inhibits the TSC-1/2 complex, which
then can no longer inhibit Rheb. Rheb is an activator of the mTOR complex, which
promotes protein synthesis through activation of 4E-BP1 and S6K1. Akt activation also
promotes cell survival and progression of the cell cycle.67
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involved in each specific case. For the specific case of TLR2 ligation, it has been shown
that inhibition of PI3K causes a decrease in IL-10 production by PBMCs, but an increase
in TNF-α, IL-12p40 and IL-23.5 For specific cell types, macrophages and dendritic cells
produce IL-10 upon TLR2 ligation (in macrophages the production levels are higher than
in dendritic cells), and in both cases PI3K activity is required.5 Macrophages do not
produce IL-12 in response to staphylococcal PGN, unless PI3K is inhibited. In the case of
dendritic cells, they produce IL-12 independently of PI3K activity.5 All this exemplifies
that PI3K is involved in a variety of immune responses and probably the consequences of
its activity are dependent on the stimulating ligands and on the cell type.
Numerous studies in mice support the important role of PI3K activity in TLR2
signal transduction, and consequently, in immune cells responses. It has been shown that
protein kinase Lyn and PI3K negatively regulate IL-6 and TNF-α production upon TLR2
ligation in murine bone marrow-derived macrophages75. This disruption of the TLR2MyD88-dependent signalling cascade impairs functional activation of PI3K and Rac1,
which leads to decreased phagocytosis of Lysteria monocytogenes by murine
macrophages.76 MyD88 was also shown to be a critical factor in the signal transduction
pathway from TLR2 to the PI3K/Akt and NF-κB pathways in a murine microglia cell
line, after PGN stimulation, leading to IL-1β, IL-6 and TNF-α production.77 However, the
exact role of PI3K activity in the signal transduction of different immune cell types upon
TLR2 activation is still not completely clear; nor is the precise function of all the
downstream adaptors, and most importantly, their implication in cell-type specific
responses. A model in which Mal recruits PI3K to the cell membrane through its PH
domain was proposed.78 The main results in this study showed that Akt was
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phosphorylated in macrophages stimulated with TLR1/2 and TLR2/6 agonists, and they
produced TNF-α in response to these stimuli. However, when using macrophages
deficient in Mal or MyD88 for these experiments, the Akt phosphorylation time profile
was affected. The factors affecting these changes in the Akt phosphorylation profile were
two: the adaptor that the macrophages were deficient in (Mal or MyD88), and the
heterodimer that was being ligated (TLR1/2 or TLR2/6). Furthermore, if the
macrophages were deficient in Mal or MyD88, Akt activation and TNF-α production
changed. TNF-α was completely abolished in macrophages deficient in MyD88.
Nevertheless, macrophages deficient in Mal decreased their TNF-α production upon
stimulation of TLR1/2, but increased their TNF-α production upon stimulation of
TLR2/6. Due to these differences, the model proposed in this study places Mal as an
adaptor protein that recruits MyD88 upon TLR1/2 ligation, but not after TLR2/6
ligation,78 which supports other observations.48
Finally, phagocytosis of S. aureus has also been described as an essential step for
an optimal immune response through TLR2 ligand binding. For instance, phagocytosis
was required to initiate an immune response through the TLR2/MyD88 pathway in
murine macrophages stimulated with S. aureus,79 and in human peripheral blood
stimulated with LTA.80 Furthermore, PI3K also has been shown to have a role in heatkilled S. aureus internalization, and in TNF-α and IL-10 production by monocytes.81 This
stresses the importance of the PI3K/Akt pathway as an important component of the TLR2
signal transduction, and therefore, of the immune response to S. aureus.
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Chapter 2

2

Hypothesis
2.1

Rationale and hypothesis

Even though both macrophages and dendritic cells produce IL-10 in response to PGN and
LTA, it is only dendritic cells that also produce IL-12/23p40. In addition, macrophages
are the predominant APC in mucosa, whereas dendritic cells are the predominant APC in
skin and connective tissues. Thus, if S. aureus was located in a mucosal area, such as the
respiratory tract, it would be more likely that the ensuing immune response would be
initiated by macrophages. On the other hand, if S. aureus entered the body through a skin
lesion, it is more likely that the immune response is initiated by a dendritic cell. Taken
together,

this

suggests

that

a

macrophage

would

initiate

a

predominantly

immunomodulatory response to S. aureus located in the nostrils, whereas a
predominantly pro-inflammatory response would be triggered by dendritic cells upon
encounter of S. aureus in skin and connective tissues. Therefore, the generation of an
immunomodulatory or of a pro-inflammatory response to S. aureus depends on where the
bacteria interact with the immune system. Furthermore, PI3K activity is required for IL10 production, but has no role in IL-12/23p40 production by dendritic cells. Therefore, it
is hypothesized that an IL-10 modulatory response, reflected in activation of the
PI3K/Akt pathway in macrophages, is the mechanism that takes place in the in the
nostrils, and correlates with S. aureus carriage status.
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2.2

Specific aims

This hypothesis will be addressed through 3 specific aims:
I)

To compare the immune response to S. aureus or PGN in carriers and noncarriers. For this purpose, a cohort of S. aureus nasal carriers and non-carriers
will be generated.

II)

To determine the cytokine profile of the two populations in the cohort,
including IL-10.

III)

To evaluate the correlation between IL-10 production and activation of the
PI3K/Akt pathway.
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Chapter 3

3

Materials and Methods

3.1 Selection of study subjects
Prior to participating in this study each subject was provided a letter of
information describing the study and its risks. Subsequently, informed consent was
obtained from each subject in compliance with a protocol approved by the Office of
Research Ethics at the University of Western Ontario (see Appendix A).
Subjects participating in this study were placed into one of three categories with
respect to S. aureus nasal carriage: (1) permanent carriers (carriers), (2) transient carriers
and (3) non-carriers. Carriers were defined as those subjects confirmed to have S. aureus
isolated from their nostrils every time they were tested over a period of 16 months.
Transient carriers were defined as those subjects whose carriage status was intermittently
positive at least once throughout the study period. Non-carriers were considered to be
subjects who were consistently negative for the isolation of S. aureus from their nostrils
throughout the study period.

3.2

Isolation of S. aureus from nasal swabs

Healthy subjects were swabbed with sterile cotton swabs in both nostrils. The left
and right anterior nares of each individual were firmly swabbed four times around. A new
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sterile swab was used for each subject. Immediately after swabbing, these swabs were
used to streak MacConkey agar plates without salt (Nepean, Oxoid, ON, Canada). The
choice of MacConkey agar without salt was made because it is the same one used in the
clinical laboratory of Victoria Hospital, London, ON, Canada. The plates were incubated
for 48 hours (h) at 35 ºC. Colonies with a light orange colour were picked and dispersed
in 500 µL of 1X phosphate buffered saline pH 7.3 – 7.5 (PBS) prepared from a 10X
liquid concentrate (BioShop, Burlington, ON, Canada) diluted in double distilled H2O
(ddH2O). This served as a stock for each isolate and was stored at -20 ºC until required.

3.3

Polymerase chain reaction (PCR)

To confirm visual identification of S. aureus colonies on McConkey agar plates, a
DNA fragment of 279 base pairs (bp) from the nuc gene, which encodes for a nuclease
and is specific to S. aureus was amplified by PCR from the isolated colonies.
Amplification of a 796 bp region on the 16S rRNA gene (common to all bacterial
microorganisms)82, 83 ,84 was used as a positive control. The two reactions were performed
in the same tube at the same time in a multiplex format. The sequence of the primers
(synthesized by IDT, Coralville, IA, USA) used was as follows:
Nuc1: 5’ GCG ATT GAT GGT GAT ACG GTT 3’
Nuc2: 5’ ACG CAA GCC TTG ACG AAC TAA AGC 3’
16S1: 5’ AGA GTT TGA TCA TGG CTC AG 3’
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16S2: 5’ GGA CTA CCA GGG TAT CTA AT 3’
The PCR mixes contained the following reagents: 1X Taq buffer with KCl from
stock at 10X containing 100 mM Tris-HCl (pH 8.8), 500 mM KCl and 0.8% (v/v)
Nonidet P40; 0.67 mM MgCl2; 5 mM deoxyribonucleotide triphosphate (dNTP) and 20 u
µL-1 of Taq Polymerase; all from Fermentas, Burlington, ON, Canada. Primers were
added to a concentration of 2.5 µM, and 2 µL of stock from S. aureus isolates was used
as a source of genomic DNA template. Every PCR reaction had a final volume of 25 µL,
and a reaction with ddH2O added instead of template was used as a negative control. The
reactions were carried out in a PTC-100 Peltier Thermal Cycler (BioRad, Hercules, CA,
USA) or in a Biometra T Gradient (Montreal Biotech Inc., Kirkland, PQ, Canada). Next,
they were subjected to an initial template melting by incubating at 95 ºC for 5 minutes,
followed by 30 cycles of melting at 94 ºC for 30 seconds, annealing at 55 ºC for 30
seconds and extension at 72 ºC for 30 seconds. The last cycle was followed by a final
extension at 72 ºC for 8 minutes. The resulting PCR amplification products were stored at
4 ºC until they were analysed.

3.4

DNA electrophoresis of PCR products on agarose

gels
DNA sample buffer (6X stock, Fermentas, Burlington, ON, Canada) was added to
the total volume of the PCR mix after completion of the PCR, and run on a 1.5% agarose
gel with 0.02 µg mL-1 ethidium bromide in 1X Tris-acetate-ethylenediaminetetraacetic
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acid (EDTA) buffer (TAE Buffer; 50X Liquid Concentrate, BioShop, Burlington, ON,
Canada) in ddH2O at 120 v at room temperature (RT) for 15 minutes. The presence of
the 279 bp band from a candidate colony positively confirmed the bacterial colony as
being S. aureus.

3.5

Purification of PCR products

For purification of the two PCR products of 279 and 796 bp, which belong to
fragments of nuc and 16S rRNA respectively, one PCR for each pair of primers was run
separately and the volume corresponding to the primers was substituted for ddH2O. Next,
the QUIAquick PCR Purification Kit form Quiagen (Toronto, ON, Canada) was used on
the PCR mixes with the product to purify it. Briefly, the PCR mix with the products was
solubilised with a high-salt buffer, which favours DNA binding to a silica membrane,
through which the new mix flew through. DNA was eluted from the membrane with a
low-salt buffer.

3.6

PCR products cloning

To confirm the nature of the PCR products by sequencing, the two different PCR
products were subcloned into the pCR®4-TOPO® vector using the TOPO® TA kit for
sequencing (Invitrogen, Burlington, ON, Canada). Briefly, Taq polymerase leaves a
hanging adenine (A) at the 3’ end of all its amplification products. This A can be paired
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with a hanging thymine (T) at each end of a linearized vector (TOPO®). This vector has
the recognition site sequence for topoisomerase I activity 5’-(C/T)CCTT-3’ at both ends,
and attached to them, a topoisomerse I enzyme, which can act as a ligase.

3.7

Heat shock transformation of E. coli DH5-α

competent cells
After ligation of the two PCR products into the pCR®4-TOPO® vector, each
reaction was added to 50 µL of chemically competent E. coli DH5-α (Invitrogen,
Burlington, ON, Canada), and these mixes were left on ice for 20 minutes. Next, they
were subjected to a heat shock at 42 ºC for 30 seconds, quenched on ice and 250 µL of
super optimal broth with catabolite repression (SOC) media (Invitrogen, Burlington, ON,
Canada) was added immediately. Then, it was incubated at 37 ºC for 1 hour shaking.
Next, this mix was plated in LB-Miller agar plates (6 g L-1 of LB powdered media and 4
g L-1 of agar, BioShop, Burlington, ON, Canada) with 100 µg mL-1 ampicillin (BioShop,
Burlington, ON, Canada) and preplated with 50 µL of 4% 5-bromo-4-chloro-indolyl-β-Dgalactopyranoside (X-Gal, BioShop, Burlington, ON, Canada) and 25 µL of 0.1 M
isopropyl β-D-1-thiogalactopyranoside (IPTG, BioShop, Burlington, ON, Canada) and
incubated at 37 ºC overnight (O/N). Positively transformed bacteria survived on LB agar
with ampicillin plates. Only bacteria that had incorporated the PCR products into the
vector were unable to metabolize the X-Gal, and therefore, generated white coloured
colonies. Bacteria with the vector, but without the insert generated blue colonies instead.
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3.8

Bacterial DNA isolation

White colonies from each transformation were picked with a sterile pipette tip,
inoculated in 5 mL of LB Miller Broth (6 g L-1, BioShop, Burlington, ON, Canada) with
100 µg mL-1 ampicillin and grown at 37 ºC shaking O/N. On the next day, DNA was
purified from the bacterial culture using the QUIAprep Spin Miniprep Kit (Quiagen,
Toronto, ON, Canada). DNA concentration was measured using a NanoDrop® ND-1000
Spectrophotometer (Thermo-Scientific, Logan, UT, USA). Briefly, bacteria were lysed
under alkaline conditions, and then the lysates were neutralized and adjusted to high-salt
binding conditions. DNA bound to a silica membrane, whereas the rest of the lysate
flowed through. Next, DNA was washed and eluted with a low-salt buffer.

3.9

DNA sequencing

All sequencing reactions were performed by the staff at the Robarts Research
Institute Core DNA Sequencing Facility at the University of Western Ontario, using a
3730 DNA sequencer or an Applied Biosystems PRISM 377 (Applied Biosystems Inc,
Foster City, CA, USA). The primers used for sequencing were the M13 Forward (5´GTAAAACGACGGCCAG-3´) and M13 Reverse (5´-CAGGAAACAGCTATGAC-3´)
and they were provided by the Robarts Sequencing Facility.
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3.10

Bacteria heat-killing

Sterile pipette tips were used to scratch the surface of the frozen -20 ºC PBS
stocks that had previously been confirmed as S. aureus. he tips were used to streak
MacConkey agar plates without salt which were then incubated for 48 h at 35 ºC. PCR
was run in one of the colonies to confirm that a pure colony of S. aureus had grown.
After confirmation, one S. aureus colony from this new plate was picked and inoculated
into 150 mL of LB Miller Broth. The culture was incubated at 37 ºC with shaking
overnight O/N. The following day, 10-6, 10-7 and 10-8 dilutions of the S. aureus culture
were plated on LB agar and grown O/N at 37 ºC in order to obtain the S. aureus cell
density (colony forming units; CFUs) in the culture prior to the heat killing. Also, 2 µL of
the culture were taken as template for PCR to confirm that it was S. aureus. Then, the
flasks with the S. aureus cultures were incubated in a water bath at 88 ºC for 20 minutes.
Next, to confirm that the heat-killing was effective, 100 µL from each S. aureus culture
was plated on LB agar plates and incubated O/N at 37 ºC. This allows any S. aureus
bacteria that survived the heat-killing to grow. Then the cultures were centrifuged at 9335
x g for 15 minutes, the supernatants discarded, and the pellet was resuspended in 1X PBS
and the previous washing procedure was repeated two more times. After the last wash,
the pellets were resuspended in 10 mL of 1X PBS and kept at 4 ºC. On the following day,
the colonies on the LB agar plates were counted. The microbial CFU in the heat-killed
cell suspension were calculated by determining the viable cell count on the LB agar
plates that were inoculated prior to the heat-killing step, while plating of the bacterial
suspension after the heat-killing procedure was used to confirm the efficacy of the heatkilling treatment.
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3.11

Isolation of peripheral blood mononuclear cells

(PBMCs)
Based on the results of the nasal swab and confirmatory PCR for S. aureus
participants classified as healthy non-carriers or S. aureus carriers (subjects who
remained S. aureus positive throughout the study time) were selected to have their blood
drawn for analysis. One hundred twenty mL of blood was collected from each donor in
syringes pre-coated with heparin (Pharmaceutical Partners of Canada, Richmond Hill,
ON, Canada). PBMCs were isolated by Ficoll-Histopaque (Ficoll-Plaque PLUS, GE
Healthcare Bio-sciences AB, Uppsala, Sweden) density gradient centrifugation. Four 50
mL tubes per 120 mL of blood were used the following way: thirty mL of whole blood
was layered on top of 20 mL of Ficoll-Histopaque and centrifuged at 740 x g for 30
minutes at RT, with the break turned off. PBMCs were found in a thin layer between the
plasma layer and the Ficoll-Histopaque layer. The PBMC layer was removed, washed
with PBS, and centrifuged for 10 minutes at 514 x g and 4 ºC. Red blood cells were lysed
by resuspending the pellet in 0.2% NaCl for 1 minute. The lysis reaction was stopped by
adding an equal volume of 1.6% NaCl. PBMCs were centrifuged again for 10 minutes at
276 x g and 4 ºC. The pellets were resuspended in Roswell Park Memorial Institute
(RPMI) 1640 (RPMI HyClone, Thermo Scientific, Logan, UT, USA) complete media
supplemented with 10% fetal calf serum (RPMI 10%) and centrifuged again for 10
minutes at 185 x g and 4 ºC. Next, cells were resuspended in 10 mL of RPMI 10% and
counted by diluting them 1:1 in Trypan Blue (Thermo Scientific, Logan, UT, USA) and
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plating them in a hemocytometer (Reichert, Buffalo, NY, USA). The microscope used to
count was a Nikon TMS-F (Melville, NY, USA). After calculating the total number of
PBMCs, they were distributed according to the quantity required for the different
stimulations, as it is described below.

3.12
3.12.1

Cell stimulation
Cell stimulation for western blotting and intracellular
signalling enzyme-linked immunosorbent assay (ELISA)

Five million (for western blotting), 1.0x107 (for intracellular signalling ELISAs)
PBMCs in 200 µL of RPMI 10% were used per time point. PBMCs were pre-incubated
for 5 minutes at 37 ºC shaking. Heat-killed S. aureus (6.25x106 CFU) diluted in 10 µL of
RPMI 10% were added to the PBMCs and the activation took place at 37 ºC shaking for
increasing time periods (i.e. activation was stopped after 30 s, 1 m, 5 m, 15 m, 30 m and
60 m). PBMCs were also stimulated with 10 µg mL-1 PGN for the same time points, or
with 1 mM pervanadate for 2 m, as previously described.85 Activation was stopped by
adding 600 µL of cell washing buffer [1X PBS containing 400 µM sodium orthovanadate
(Sigma-Aldrich, Oakville, ON, Canada) and 400 µM EDTA (BioShop, Burlington, ON,
Canada)] at 4 ºC.
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3.12.2

Cell stimulation for cytokine ELISA

Two hundred thousand PBMCs in 100 µL of RPMI 10% were plated per well in
96-well U-bottom plates. Each activation condition was performed in triplicates. PBMCs
from 9 carriers, 10 non-carriers and 4 transient carriers were exposed to three different
heat-killed S. aureus isolates (for carriers one of them was their own). PBMCs from 6
carriers, 7 non-carriers and 4 transient carriers were exposed to Bacillus subtilis (B.
subtilis). PBMCs from 7 carriers, 5 non-carriers and 1 transient carrier were exposed to
staphylococcal PGN (Sigma-Aldrich, Oakville, ON, Canada). And PBMCs from 4
carriers, 2 non-carriers and 1 transient carrier were exposed to Concanavalin A (ConA;
Sigma-Aldrich, Oakville, ON, Canada). PBMCs were stimulated with 1.25x105 –
1.15x108 heat-killed S. aureus or CFUs diluted in 100 µL of RPMI 10%, as well as with
0.1 - 100 µg mL-1 (final concentration) PGN or 1 µg mL-1 (final concentration) ConA86
for 18 hours (h). Next, supernatants were stored at -20 ºC until cytokines were measured
by ELISA.

3.13

Lysis of PBMCs

PBMCs in cell washing buffer were pelleted at 12800 x g for 1 minute and
resuspended in lysis buffer [1% Triton X-100, 150 mM NaCl, 10 mM Tris pH7.6, 5 mM
EDTA, 1 mM sodium orthovanadate, 10 µg mL-1 leupeptin, 10 µg mL-1 aprotinin (all
from Bioshop, Burlington, ON, Canada), 25 µM p-nitrophenyl-p’ guanidinobenzoate
(NPGB, Fisher-Scientific, Ottawa, ON, Canada)], as previously described4. One hundred
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µL of lysis buffer was added to pellets of 5x106 PBMCs for western blotting.
Alternatively 62.5 µL of lysis buffer was added to 1 x106 of PBMCs for intracellular
signalling ELISA for 30 minutes at 4 ºC. Cell debris was pelleted at 15500 x g, 4 ºC for
10 minutes and supernatants were recovered and either used immediately or frozen at -80
o

C.

3.14

Protein quantification in whole cell lysates

Protein was measured in whole cell lysates using the BCA protein assay kit
(Thermo Scientific, Logan, UT, USA). Briefly, proteins in the whole cell lysates reduce
Cu2+ to Cu1+, forming a complex, in an alkaline environment. Next, bicinchoninic acid
(BCA) reacts with the reduced cations and forms a purple coloured complex, which
exhibits a linear absorbance at 562 nm with increasing protein concentrations.

3.15

Sodium

dodecyl

sulfate

polyacrylamide

gel

electrophoresis (SDS-PAGE) and western blotting
Western blotting was performed as previously described.87 Briefly, 96 µL of
whole cell lysates were mixed with 32 µL of sample buffer containing 8% sodium
dodecyl sulfate (SDS), 8% β-mercaptoethanol, 250 mM Tris (pH 6.8), 40% glycerol, 2%
Bromophenol Blue (all from BioShop Burlington, ON, Canada). Then, these mixtures
were boiled at 95 ºC for 5 minutes and resolved by standard SDS-PAGE using 10% gels.
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For making one separating gel the following reagents were used: 2 mL of ddH2O, 1.7 mL
of 30% Acrylamide/Bis solution, 0.05 mL of 10% SDS, 0.05 mL of 10% ammonium
persulphate (APS) (all from BioRad, Hercules, CA, USA), 1.3 mL of 1.5 M Tris (pH
8.8), and 2 µL of tetramethylethylenediamine (TEMED) (both from BioShop, Burlington,
ON, Canada). To make one stacking gel, which is situated above the separating gel, the
following reagents were used: 0.68 mL of ddH2O, 0.17 mL of 30% Acrylamide/Bis
solution, 0.01 mL of 10% SDS-PAGE, 0.01 mL of APS, 0.13 mL of 0.5 M Tris (pH 6.8)
and 1 µL of TEMED. The gels were run at 120 v in running buffer [144.25 g L-1 Glycine,
30.5 g L-1 Tris, 10 g L-1 SDS (BioShop, Burlington, ON, Canada), in a mini Protean Tetra
Cell System from BioRad (Hercules, CA, USA). Gels were run till the sample dye ran off
the bottom of the gel. Proteins were transferred to a polyvinylidene fluoride (PVDF)
membrane (BioRad, Hercules, CA, USA) by semi-dry transfer for 35 minutes at 16 mV
with a resistance limit of 0.16 Amps/membrane in transfer buffer (3.03 g L-1 Tris and
14.4 g L-1 Glycine) using a Trans-Blot transfer system from BioRad (Hercules, CA,
USA). After transfer, gels were stained with Coomassie Blue [0.25 g of Coomassie
Brilliant Blue Dye (Sigma-Aldrich, Oakville, ON, Canada) in 90 mL of methanol:ddH2O
(1:1 v/v) and 10 mL of glacial acetic acid (EMD Chemicals Inc., Darmstadt, Germany;
BioShop, Burlington, ON, Canada; respectively)]. Membranes were incubated O/N at 4
ºC with shaking in 1X blocking solution [BM Chemiluminescence Blotting reagent
(Roche, Indianapolis, IN, USA)] diluted in Tris-buffered saline (TBS) containing 50 mM
Tris, 150 mM NaCl and 0.02% NaN3. Next, membranes were incubated for 2 hours at RT
with shaking in the primary antibody [rabbit monoclonal anti-Phospho-Akt (Ser473)
antibody (1:1000), rabbit anti-Akt antibody (1:1000), rabbit monoclonal anti-Phospho-
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p44/42 MAPK (Thr202/Tyr204) antibody (1:1000) all from Cell Signalling, Danvers,
MA, USA; rabbit polyclonal anti-ERK 1/2 (MAPK) antibody (1:5000), Assaydesigns
Stressgen, Brockville, ON, Canada; mouse monoclonal anti-GAPDH antibody (1:1000),
Chemicon International, Temecula, CA, USA] in TBS-Tween (TBS-T; containing 50
mM Tris, 150 mM NaCl and 0.05% Tween 20) with 0.2% NaN3 and 0.5% BSA. Then,
membranes were washed 3 times for 5, 7 and 10 minutes with TBS-T and the secondary
antibody diluted in TBS-T [1:30,000 for goat anti-rabbit (BioRad, Hercules, CA, USA)
and 1:10,000 for goat anti-mouse (GE Healthcare, Little Chalfont, UK)] was added and
membranes were incubated for 20-45 minutes at RT with shaking. Next, membranes were
washed again as indicated above and incubated for 1 minute with BM Chemiluminescent
blotting substrate (Roche, Indianapolis, IN, USA. Images of the membranes were
obtained using a De-500 Alpha Innotech MultiImage II light cabinet.

3.16

Densitometry analysis

Protein bands from the western blot images were analyzed using a De-500 Alpha
Innotech MultiImage II light cabinet and its software.

3.17

Cytokine ELISA

ELISA was performed as previously described.88 Ninety six-well plates (Thermo
Scientific, Logan, UT, USA) were coated with capture antibody for IL-10 (JES3-9D7,
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eBioscience, San Diego, CA, USA) or TNF-α (MAB1, eBiosience, San Diego, CA, USA)
diluted in 1X coating buffer (eBioscience, San Diego, CA, USA) and incubated O/N at
4ºC. The following day, plates were washed 5 times with ELISA wash buffer (1X PBS,
0.05% Tween-20), and incubated for 1 hour at RT with 200 µL/well of 1X assay diluent
as provided by the manufacturer (eBioscience, San Diego, CA, USA). Plates were then
washed as indicated above and samples were added to triplicate wells, and diluted 1:10 in
1X assay diluent as supplied by the manufacturer of the kit, up to 100 µL/well. One
hundred µL of standard concentrations of IL-10 (eBioscience, San Diego, CA, USA) and
TNF-α (eBioscience, San Diego, CA, USA) were added to the same plate as well. Both
standards and samples were incubated for 2 hours at RT. Then, plates were washed 5
times as indicated above and 100 µL/well of detection antibody for IL-10 (JES3-12G8,
eBioscience, CA, USA) or TNF-α (MAB11, eBioscience, San Diego, CA, USA) diluted
in 1X assay diluent was added. Plates were incubated for 1 hour at RT. Next, the plates
were washed 5 times as indicated above and then 100 µL/well of Avidin-horseradish
peroxidise (HRP) (eBioscience, San Diego, CA, USA) diluted in 1X assay diluent 1:250
was added, and plates were incubated for 30 minutes at RT. Then, plates were washed
seven times with ELISA wash buffer. One hundred µL/well of substrate solution (1X
TMB solution, eBioscience, CA, USA) was then added to each well and incubated for
approximately 15 minutes at RT. Then, 50 µL of stop solution (2N H2SO4) was added to
each well and absorbance was measured using a microplate reader model 680 from
BioRad (Hercules, CA, USA) or a v max kinetic microplate reader from Molecular
Devices (Sunnyvale, CA, USA) at 450 nm and at 570 nm. The final absorbance was
determined by subtracting the values at 570 nm from the 450 nm reading. The
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concentration of cytokine was calculated from the best fitted line from the known
cytokine standard concentrations.

3.18

Sandwich ELISA antibody pair for phospho-Akt

(Ser473), total Akt, phospho-ERK1 (T202/Y204)/ERK2
(T185/Y187), and total ERK
For phospho (p)-Akt and total Akt, the manufacturer’s protocol was followed as
provided by Cell Signaling (Danvers, MA, USA) and employing the PathScan phosphoAkt1 (Ser473) Sandwich ELISA antibody pair and by Cell Signalling (Danvers, MA,
USA) PathScan total Akt1 Sandwich ELISA antibody pair. For p-ERK1 (T202/Y204)
ERK2 (T185/Y187) and total ERK1/2, the protocol was followed as provided by R&D
Systems (Minneapolis, MN, USA) using the DuoSet #DYC1018B-2, DYC1018B-5,
DYC 1230C-2 and DYC1230C-5 antibodies. Briefly the general ELISA procedure was as
follows: 96-well plates were coated with a capture antibody (p-Akt, Akt, p-ERK or ERK)
and incubated O/N at 4 ºC. On the following day, after washing and blocking, whole cell
lysates (diluted 1:2 in lysis buffer) were added and incubated O/N at 4 ºC. On the
following day, capture antibody was added, followed by the avidin-HRP antibody,
substrate solution and stop solution. Absorbance was read at 450 nm (A450) and the A450
value from a lysis buffer control was subtracted from the absorbance values from the
assay samples. The ratio of the A450 from the measurements of the phosphorylated form
over the totals, for both Akt and ERK respectively, was calculated and graphed.
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3.19

Statistical analysis

Data were analysed using a 2-way analysis of variance (ANOVA) with a
Bonferroni post-test analysis, using the GraphPad Prism software. p values < 0.05 were
considered significant. Specific p values were calculated from the t and the degrees of
freedom values using GraphPad Prism softaware QuickCalcs p value calculator online.

3.20

Alignment of nucleotide sequences

Nucleotide sequence analysis was performed using the basic local alignment
search tool (BLAST) available online, from the National Center for Biothechnology
Information (NCBI). The sequenced products were compared to the NCBI nucleotide
collection.
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Chapter 4

4

Results

4.1 Specific aim I: Generation of a cohort of S. aureus
carriers
4.1.1

Nasal swabs, S. aureus culture and confirmation by PCR
To build the cohort, the first step was to assign each subject to the correct S.

aureus nasal carriage group (carriers, transient carriers or non-carriers, as explained in the
previous chapter), which required an analysis of the presence or absence of S. aureus in
the nostrils. To achieve this, nose swabs from healthy subjects were plated on McConkey
agar without salt and grown for 48 hours. Colonies with a light orange color (Fig. 4.1)
were selected as potential S. aureus candidates, diluted in PBS and subjected to PCR to
confirm the colony as being S. aureus. The PCR amplified a 796 bp fragment from 16S
rRNA common to all microorganisms as a positive control, as well as a 179 bp fragment
of the S. aureus specific nuc, which encodes a nuclease. Therefore, after performing the
PCR, all colonies should have 16S rRNA amplification, but only S. aureus colonies
should yield a nuc amplification product (Fig. 4.2).
To confirm that the PCR products were indeed derived from the 16S rRNA and
the S. aureus nuc, they were purified from the PCR mix and cloned into TOPO® vectors.
One clone containing the correct size insert for each product was sequenced
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Figure 4.1: Representative appearance of S. aureus colonies from a nose
swab.
Nasal swabs from healthy subjects were used to streak MacConkey agar without
salt plates. S. aureus colonies in the upper area of the picture show a light orange colour
and are within blue circles.
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Figure 4.2: Representative 16S and nuc PCR products run in an agarose gel.
Potential S. aureus colonies from nasal swabs from different subjects (A to F)
were dispersed in PBS and used as a source of template for 16S and nuc PCR
amplification. E. coli was used as a positive control and lack of template as a negative
control. Presence of the nuc band is indicative of S. aureus nasal carriage.
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using M13 primers, and the result was analyzed by nucleotide sequence analysis. Partial
sequences from both the 16S and the nuc PCR products were obtained, and found to have
100% and 99% homology to the 16S rRNA (NCBI accession number: gb JN652903.1)
and nuc (NCBI accession number: gb EF529606.1) sequences of S. aureus over a span of
36 nucleotides (nt) and 165 nt respectively.

4.1.2

Demographics of the cohort
To generate the cohort, nasal swabs from 126 subjects were collected over a 16

month (mo) period and tested for the presence of S. aureus. One hundred and two of the
tested subjects were non-carriers (81%), 18 (14%) were carriers and 6 (5%) were
transient carriers. The gender distribution in the overall cohort was 51% male and 49%
female. These percentages remained quite similar among the different carriage status
groups, being 50% male and 50% female in both carriers and transient carriers, and 51%
male and 49% female in non-carriers. Regarding the age of the cohort, the majority of the
tested subjects were between 18 and 39 years of age (y), with an average age of 22.2 y,
and 17% of the subjects in the cohort were 40 y or older. The percentage of those subjects
40 y or older increased in the carriers group to 33%, with an average age of the carriers
between 18 and 39 y being 24.2 y. There were no transient carriers 40 y or older, and
their average age was 22.3 y. Finally 15% of the non-carriers were 40 y, and the average
age was 21.9 y in the age range between 18 and 39 y. All the different average ages in the
groups were statistically similar to one another, as well as to the average age of the
overall cohort, in all cases in the age range between 18 and 39 y (Table 1).
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Number of subjects (percentage; average; standard
deviation)
Number of subjects
(percentage)

Total

Carriers
Transient
carriers
Noncarriers

126 (100%)

18 (14%)

6 (5%)

102 (81%)

Gender
Males

64 (51%)

9 (50%)

3 (50%)

52 (51%)

Age (years)

Females

18-39

≥40

62 (49%)

105 (83%;
av.=22.2; std.
dev.=3.2)

21 (17%)

9 (50%)

12 (67%;
av.=24.2; std.
dev.=5.4 )

6 (33%)

3 (50%)

6 (100%;
av.=22.3; std.
dev.=0.5)

0 (0%)

50 (49%)

87 (89%;
av.=21.9; std.
dev.=2.9)

15 (15%)

Table 1: Demographic profile of S. aureus nasal carriage cohort.
Calculations are presented for number of subjects, percentages, average age and
standard deviation for all the subjects tested for S. aureus nasal carriage over the length
of 16 months. Percentages, average age and standard deviation were calculated according
to the number of subjects classified in each row according to their carriage status. av:
average, std. dev.: standard deviation.
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Some of the subjects in the cohort were selected for further analyses of their
cytokine profile and/or Akt and ERK activation response. The demographic and carriage
profiles of these subjects are displayed in Tables 2, 3 and 4. Table 5 is a consolidated
summary of these subjects selected for further studies. The 9 selected carriers are 56%
male and 44% female. Twenty two percent of them were 40 y or older, and the average
age of those between the ages of 18 and 39 y was 25.4. Carriers selected for further
studies had been swabbed an average of 2.6 times. Four transient carriers were also
selected for further studies, two male and two female. None of the transient carriers were
40 y or older and the average age in this group was 22.3 y. The average number of swabs
for these subjects was 3.3. Lastly, 10 non-carriers were selected for further analysis,
comprised of five males and five females. In this group there was the same number of
males and females. Ten percent of the subjects were 40 y or older, and the average age of
the rest (those between the ages of 18 and 39 y) was 24.4 y. Subjects in the non-carriers
group were swabbed an average of 2.3 times (Table 5).
The generation of the cohort was an ongoing process throughout the 16 months in
which this study was conducted. Available donors that met the requirements were
selected for further studies that would test the differences between the immune responses
from carriers and non-carriers.
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Subject #

Gender

Age

Detection of S. aureus by PCR

1

M

32

+

+

2

M

21

+

+

3

M

≥40

+

+

4

F

21

+

+

5

M

19

+

+

6

F

29

+

+

7

F

20

+

+

8

M

36

+

+

9

F

≥40

+

+

+

+

+

+

+

Table 2: Profile of carriers selected for further analysis.
Gender, age, and carriage profile based on PCR results of all the nasal swabs of
those subjects from the generated cohort that were S. aureus nasal carriers and were
selected for further studies using their PBMCs.
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Subject #

Gender

Age

Detection of S. aureus by PCR

10

M

22

-

+

+

11

M

22

-

-

-

12

F

23

-

-

+

13

F

22

-

+

-

+

Table 3: Profile of transient carriers selected for further analysis.
Gender, age, and carriage profile based on PCR results of all the nasal swabs of
those subjects from the generated cohort that were S. aureus transient nasal carriers and
were selected for further studies using their PBMCs.
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Subject #

Gender

Age

Detection of S. aureus by PCR

14

F

≥40

-

-

15

F

20

-

-

16

F

26

-

-

17

M

22

-

-

18

M

24

-

-

19

M

22

-

-

20

F

24

-

-

21

F

24

-

-

22

M

30

-

-

23

M

28

-

-

-

-

-

Table 4: Profile of non-carriers selected for further analysis.
Gender, age and carriage profile based on PCR results of all the nasal swabs of
those subjects from the generated cohort that were S. aureus non-carriers and were
selected for further studies using their PBMCs.
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Number of subjects (percentage; average age)
Gender

number

Age (years)

Nasal carriage status
(number of subjects)

Average
of
swabs

M

F

18-39

≥40

Carriers (9)

5
(56%)

4
(44%)

7 (78%; average of
25.4)

2
(22%)

2.6

Transient carriers (4)

2
(50%)

2
(50%)

4 (100%; average of
22.3)

0 (0%)

3.3

Non-carriers (10)

5
(50%)

5
(50%)

9 (90%; average of
24.4)

1
(10%)

2.3

Table 5: Summary of the profiles of subjects chosen for further analysis.
Summary of the number of subjects and percentages of gender and age
distribution, as well as average number of times that they were swabbed from the subjects
selected for further studies on their PBMCs.
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4.2

Specific aim II: Determination of the cytokine

profile of carriers and non-carriers
4.2.1

Cytokine responses to heat-killed S. aureus
To study the differences in the immune response to S. aureus between carriers and

non-carriers, cytokine production by PBMCs from subjects in these groups was
measured. Since the main question of this thesis was whether IL-10 plays a role in
determining the nasal carrier status of a subject, the cytokines IL-10 and TNF-α were
measured. TNF-α production was used as a representative measure of the proinflammatory response. PBMCs were isolated from subjects whose carrier status had
been determined previously at least once, and it was re-tested again for confirmation
every time their blood was drawn. PBMCs from carriers and non-carriers were exposed
for 18 hours to increasing levels (CFU) of heat-killed S. aureus. The heat-killed S. aureus
bacteria that were used came from the carrier’s autologous nasal S. aureus isolate,
subsequent to growing and heat-killing the isolate. PBMCs from each carrier were
exposed to their autologous isolate, as well as to two other heterologous (different
carriers’ isolates). The non-carriers were exposed to the same isolates as the carriers, i.e.:
to all the carriers’ S. aureus nasal isolates. Cytokine production was measured by ELISA
in the supernatants. The IL-10 responses from carriers exposed to their autologous
isolate, and exposed to heterologous isolates were very similar (Fig. 4.3A). They
increased and peaked at 1.25x106 and 1.25x107 CFUs, and then decreased. The TNF-α
response from carriers exposed to their autologous isolate and to heterologous isolates
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(Fig. 4.3B) were also very similar, but, as opposed to the trend seen for IL-10 production,
TNF-α responses increased until they reached a plateau, at 1.25x107 to 1.25x108 CFU.
Although there were no significant differences (Table 6) between the IL-10
responses of carriers exposed to their autologous isolates and non-carriers exposed to all
the carriers’ isolates (Fig. 4.4A), there was a trend for the IL-10 response to be lower in
non-carriers, independently of the CFU concentration. The IL-10 dose response observed
for non-carriers was similar to the ones from carriers in Fig. 4.3A. In both of them (Fig.
4.3A and 4.4A), IL-10 production peaked at 1.25x106 or 1.25x107 CFU before
decreasing. The TNF-α dose response from non-carriers exposed to all the carriers’
isolates was similar to those of carriers shown in Figure 4.3B: increasing until they
reached a plateau from 1.25x107 to 1.25x108 heat-killed S. aureus CFU (Fig. 4.4B).
To study the cytokine response by PBMCs from transient carriers exposed to
heterologous heat-killed S. aureus nasal isolates, the same experiment as above was
performed. IL-10 and TNF-α responses were compared to the carriers and non-carrier
responses showed in Fig. 4.3 and Fig. 4.4. The IL-10 response from transient carriers
appeared to be always lower than the IL-10 responses from carriers (Fig. 4.5A), but these
differences were not statistically significant. Interestingly, the IL-10 response from
carriers exposed to heterologous was significantly higher (p<0.05) than the one from noncarriers at the 1.25x108 CFUs stimulation (Fig. 4.5A). Regarding the TNF-α response
from transient carriers, it was statistically similar to the TNF-α responses from carriers
and non-carriers, although the trend appeared to be higher at the highest level of heatkilled S. aureus CFU used (Fig. 4.5B).
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Figure 4.3: Cytokine production by PBMCs from carriers exposed to
autologous and heterologous S. aureus isolates.
PBMCs from carriers (carriers N=9, n=1-3, total=14) and were exposed to
increasing of heat-killed S. aureus CFUs for 18 h from their autologous of from two
heterologous isolates. The cytokine concentration in the supernatants was measured by
ELISA (IL-10: A and TNF-α: B).
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Figure 4.4: Cytokine production by PBMCs from carriers exposed to their
autologous S. aureus isolate and from non-carriers exposed to the carriers’ isolates.
PBMCs from carriers (carriers N=9, n=1-3, total=14) and non-carriers (N=10,
n=1-3 total=1) were exposed to increasing of heat-killed S. aureus CFUs for 18 h from
the carriers’ isolates. The cytokine concentration in the supernatants was measured by
ELISA (IL-10: A and TNF-α: B).
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Amount of heat-killed S. aureus
CFUs

p-value of the difference between carriers and
non-carriers

0

0.8819

1.25x105

0.3236

1.25x106

0.0874

1.25x107

0.2343

1.25x108

0.1552

Table 6: p values of the differences in IL-10 production between carriers
exposed to autologous isolates and non-carriers.
p values calculated for the differences in IL-10 production by PBMCs from
carriers exposed to their autologous isolates and non-carriers in response to increasing
levels of heat-killed S. aureus CFUs.
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Figure 4.5: Cytokine response from PBMCs from carriers, non-carriers and
transient carriers exposed to heterologous isolates of heat-killed S. aureus.
PBMCs from carriers, non-carriers and transient carriers were exposed to
increasing of heat-killed S. aureus CFUs (carriers N=9, n=1-3 total=14; transient carriers
N=4, n=4) for 18 hours. The cytokine concentration in the supernatants was measured by
ELISA (IL-10: A and TNF-α: B). * p < 0.05.
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4.2.2

Cytokine responses to staphylococcal PGN
Peptidoglycan (PGN) is the main component of the staphylococcal cell wall, and

it contains TLR2 ligands that elicit a cytokine response in PBMCs.5 To test if PGN alone
could elicit the same cytokine responses that were observed following stimulation with
whole heat-killed S. aureus, we stimulated PBMCs from carriers, transient carriers and
non-carriers with increasing concentrations of PGN. It was observed that the three
population groups displayed different IL-10 responses to increasing PGN concentrations
(Fig. 4.6). Although, the differences were not statistically significant, the carriers’ IL-10
response tended to be greater than those observed for the transient carriers or the noncarriers, at the higher concentrations of PGN employed. This tendency is consistent with
the results obtained with the heat-killed S. aureus. The IL-10 response by PBMCs from
carriers and non-carriers peaked at the 10 µg mL-1 PGN, whereas the IL-10 response by
PBMCs from transient carriers showed an increasing IL-10 dose response to PGN,
reaching a plateau between 10 and 100 µg mL-1 PGN (Fig. 4.6A). The TNF-α responses
from the three groups were similar, showing an increasing dose response to PGN (Fig.
4.6B).

4.2.3

Cytokine responses to B. subtilis
To confirm that the apparent differential trend in the IL-10 response between

carriers and non-carriers was specific to S. aureus, we exposed PBMCs from carriers,
transient carriers and non-carriers exposed to B. subtilis, another Gram positive
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Figure 4.6: Cytokine production by PBMCs from carriers, non-carriers and
transient carriers exposed to PGN.
PBMCs from carriers (N=7, n=7), non-carriers (N=5, n=5) and transient carrier
(N=1, n=1) were exposed to 0.1 - 100 µg mL-1 PGN for 18 hours. The cytokine
concentration in the supernatants was measured by ELISA (A: IL-10, B: TNF-α).
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Figure 4.7: Cytokine production by PBMCs from carriers, non-carriers and
transient carriers exposed to heat-killed B. subtilis.
PBMCs from permanent carriers (carriers; N=6, n=1-3, total=11), non-carriers
(N=7, n=1-3, total=8) and transient carriers (N=4, n=1-3, total=6) were exposed to
increasing heat-killed B. subtilis CFUs for 18 hours. The cytokine concentration in the
supernatants was measured by ELISA (A: IL-10, B: TNF-α).
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Figure 4.8: Cytokine response by PBMCs from carriers, non-carriers and
transient carriers exposed to ConA.
PBMCs from permanent carriers (carriers; N=4, n=1-3, total=4), non-carriers
(N=2, n=2) and transient carrier (N=1, n=1) were exposed to 1 µg mL-1 ConA for 18 h.
The cytokine concentration in the supernatants was measured by ELISA (A: IL-10, B:
TNF-α).
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bacterium. The PBMCs from subjects in the three groups were exposed to B. subtilis at
the same range of CFU employed for the S. aureus dose response experiments. IL-10
production peaked at 1.25x107 for all the groups before decreasing at 1.25x108 for
carriers while reaching a plateau for transient carriers and non-carriers (Fig. 4.7A). These
differences did not reach statistical significance. However, the TNF-α response to heatkilled B. subtilis increased as the CFU dose increased for all the three groups (Fig. 4.7B).
To confirm that the isolated PBMCs were equally responsive, we stimulated them
with concanavalin A (ConA), showing that PBMCs from carriers, transient carriers and
non-carriers could readily produce equivalent amounts of IL-10 and TNF-α when
stimulated in a non-specific manner (Fig. 4.8). Therefore, lower levels of these cytokines
upon a more specific stimulation are not a consequence of PBMCs being unresponsive,
but of that given stimulation not triggering a strong response.

4.3

Specific aim III: To correlate IL-10 production with

PI3K/Akt activity
4.3.1

Study of Akt and ERK phosphorylation in response to heatkilled S. aureus and staphylococcal PGN by western blotting
After analysing the IL-10 responses from carriers and non-carriers, we asked the

question of whether differences in the IL-10 production by PBMCs in response to heatkilled S. aureus would correlate with activation of the PI3K/Akt pathway was addressed,
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since PI3K activity is required for IL-10 production upon TLR2 ligation in
macrophages.5 To answer this question, PBMCs from carriers and non-carriers were
stimulated with heat-killed S. aureus and PGN, and Akt and ERK phosphorylation were
analyzed by western blotting at different time points, for up to 60 minutes poststimulation. ERK has also been reported to be activated upon TLR2 ligation.43
Phosphorylated forms of Akt (Fig. 4.9 and 4.10) and ERK (Fig. 4.9) were
detected by western blot upon stimulation with heat-killed S. aureus. Both the phospho
(p)-Akt and phosoho (p)-ERK signal seemed to exhibit a peak intensity at 1 and 5
minutes post-stimulation, for both the carrier (subject #8) and the non-carrier (subject
#22) tested. Even though the signal from p-Akt seemed stronger for the non-carrier the
first time the samples were analyzed, this observation was not reproduced in subsequent
experiments. Also, the intensity of the total Akt signal varied across the different samples
tested. Therefore it was difficult to derive a conclusion from these experiments. This
variation also occurred for the levels of the housekeeping protein glyceraldehyde-3phosphate dehydrogenase (GAPDH), although the differences were not as distinct as for
the total Akt levels. ERK phosphorylation also seemed to peak at 1 minute poststimulation with heat-killed S. aureus. As for p-Akt, the p-ERK levels seemed higher in
the non-carrier, than in the carrier, but also did total ERK levels, and to a lesser extent
GAPDH levels (Fig. 4.9).
A densitometry analysis of the different bands was performed. Two replicates of
two different western blots from the same samples were analyzed for p-Akt and total Akt.
Only one was suitable for analysis for p-ERK and total ERK, and all the measurements
were normalized to GAPDH levels (Fig. 4.11). The results from PBMCs stimulated with
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Figure 4.9: Akt and ERK phosphorylation upon heat-killed S. aureus
stimulation of PBMCs from a carrier and a non-carrier.
PBMCs from a carrier (subject #8) and a non-carrier (subject #22) were
stimulated with 6.25x106 per million cells of heat-killed S. aureus CFU for 30 seconds, 1,
5, 15, 30 and 60 minutes. Cells were lysed and protein concentration was measured in the
lysates, which were resolved by SDS-PAGE. Equal protein concentrations were loaded in
each lane. Following SDS-PAGE, the proteins were transferred and western blotting was
performed for p-Akt, total Akt, p-ERK, total ERK, and GAPDH.
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Figure 4.10: Akt phosphorylation upon heat-killed S. aureus stimulation of
PBMCs from a carrier and a non-carrier.
PBMCs from a carrier (subject #8) and a non-carrier (subject #22) were
stimulated with 6.25x106 per million cells of heat-killed S. aureus CFU for 30 seconds, 1,
5, 15, 30 and 60 minutes. Cells were lysed and protein concentration was measured in the
lysates, which were resolved by SDS-PAGE. Equal protein concentrations were loaded in
each lane. Following SDS-PAGE, the proteins were transferred and western blotting was
performed for p-Akt, total Akt, and GAPDH.
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Figure 4.11: Densitometry analysis of pAkt, total Akt, p-ERK and total ERK
normalized to GAPDH in PBMCs exposed to heat-killed S. aureus.
Densitometry analysis of the p-Akt, total Akt bands (n=2), p-ERK and total ERK
bands (n=1) normalized to GAPDH levels. Bands were taken from western blots of whole
cell lysates from PBMCs from a carrier (subject #8) and a non-carrier (subject #22)
which had been stimulated with 6.25x106 per million cells of heat-killed S. aureus CFU
for 30 seconds, 1, 5, 15, 30 and 60 minutes.
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Figure 4.12: Akt and ERK phosphorylation upon PGN stimulation of
PBMCs from a carrier and a non-carrier.
PBMCs from a carrier (subject #8) and a non-carrier (subject #22) were
stimulated with 10 µg mL-1 PGN for 30 seconds, 1, 5, 15, 30 and 60 minutes. Cells were
lysed and protein concentration was measured in the lysates, which were resolved by
SDS-PAGE. Equal protein concentrations were loaded in each lane. Following SDSPAGE, the proteins were transferred and western blotting was performed for p-Akt, total
Akt, p-ERK, total ERK, and GAPDH.
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Figure 4.13: Akt phosphorylation upon PGN stimulation of PBMCs from a
carrier and a non-carrier.
PBMCs from a carrier (subject #8) and a non-carrier (subject #22) were
stimulated with 10 µg mL-1 PGN for 30 seconds, 1, 5, 15, 30 and 60 minutes. Cells were
lysed and protein concentration was measured in the lysates, which were resolved by
SDS-PAGE. Equal protein concentrations were loaded in each lane. Following SDSPAGE, the proteins were transferred and western blotting was performed for p-Akt, total
Akt, and GAPDH.
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Figure 4.14: Densitometry analysis of pAkt, total Akt, p-ERK and total ERK
normalized to GAPDH in PBMCs exposed to PGN.
Densitometry analysis of the p-Akt, total Akt bands (n=2), p-ERK and total ERK
bands (n=1) normalized to GAPDH levels. Bands were taken from western blots of whole
cell lysates from PBMCs from a carrier (subject #8) and a non-carrier (subject #22) that
had been exposed to were stimulated with 10 µg mL-1 PGN for 30 seconds, 1, 5, 15, 30
and 60 minutes.
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Figure 4.15: Akt and ERK phosphorylation upon PGN stimulation of
PBMCs from a carrier and a non-carrier.
PBMCs from a carrier (subject #6) and a non-carrier (subject #23) were
stimulated with 10 µg mL-1 PGN for 30 seconds, 1, 5, 15, 30 and 60 minutes. Cells were
lysed and protein concentration was measured in the lysates, which were resolved by
SDS-PAGE. Equal protein concentrations were loaded in each lane. Following SDSPAGE, the proteins were transferred and western blotting was performed for p-Akt, total
Akt, pERK, total ERK and GAPDH.
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Figure 4.16: Akt phosphorylation upon PGN stimulation of PBMCs from a
carrier and a non-carrier.
PBMCs from a carrier (subject #6) and a non-carrier (subject #23) were
stimulated with 10 µg mL-1 PGN for 30 seconds, 1, 5, 15, 30 and 60 minutes. Cells were
lysed and protein concentration was measured in the lysates, which were resolved by
SDS-PAGE. Equal protein concentrations were loaded in each lane. Following SDSPAGE, the proteins were transferred and western blotting was performed for p-Akt, total
Akt, and GAPDH.
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Figure 4.17: Densitometry analysis of pAkt, total Akt, p-ERK and total ERK
normalized to GAPDH in PBMCs exposed to PGN.
Densitometry analysis of the p-Akt, total Akt bands (n=2), p-ERK and total ERK
bands (n=1) normalized to GAPDH levels. Bands were taken from western blots of whole
cell lysates from PBMCs from a carrier (subject #6) and a non-carrier (subject #23) that
had been exposed to were stimulated with 10 µg mL-1 PGN for 30 seconds, 1, 5, 15, 30
and 60 minutes.
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heat-killed S. aureus confirm that there is an apparent trend for p-Akt and p-ERK to peak
around the 1 and 5 minutes time points, as was suggested by western blotting results.
Nevertheless, increasing the number of repetitions and the number of subjects analyzed is
necessary to reach final conclusions.
Akt and ERK phosphorylation could also be detected upon PGN stimulation of
PBMCs from two carriers (subject #8 and subject #6) and two non-carriers (subject #22
and subject #23). Akt phosphorylation seemed to peak at 5 and 15 minutes poststimulation for all of them (Fig. 4.12, 4.13, 4.15 and 4.16). Although these results were
not conclusive due to the inconsistency in the total Akt and GAPDH levels across the
lanes, the trend in the phosphorylation peak was also observed by densitometry analysis
(Fig. 4.14A and 4.17A). p-ERK did not seem to follow any trend during the poststimulation time course, but again no conclusion can be reached due to the inconsistency
of the total ERK and GAPDH levels in these samples (Fig. 4.12). Densitometry analysis
of ERK phosphorylation also seemed very variable, although a common peak at 5
minutes post-stimulation was observed in subjects #22 (Fig. 4.14B), #6 and #23 (Fig.
4.17B). To test if these unequal levels of total Akt, total ERK, and GAPDH across the
lanes were due to suboptimal transfer of the proteins from the gel to the PVDF
membrane, gels were stained with Coomassie blue after the transfer (Appendix B).
However, there was no protein left in any of the gels after the transfer, except for the high
molecular weight proteins, none of which were in the range of our proteins of interest.
However, inefficient transfer cannot be ruled out as the cause of the unequal total Akt,
total ERK or GAPDH because no gels could be stained before transfer due to low amount
of sample. Protein degradation and a too aggressive striping of the membrane could also
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be factors leading to lack of useful loading controls
.

4.3.2

Study of Akt and ERK phosphorylation in response to heatkilled S. aureus and staphylococcal PGN by intracellular
signalling ELISA
A more quantifiable method to study phosphorylation of Akt and ERK is ELISA.

In this method, the optical density (OD) generated by a sample detecting the
phosphorylated form of the protein in question, is divided by the OD generated from the
total protein in question, regardless of its phosphorylation state. Then the ratios were
calculated for the different samples can be compared and analysed. It was not possible to
reach any conclusions from the graphs representing the phospho (p)-Akt/Akt ratio results
(Fig. 4.18A, 4.19A and 4.20A) because the ratios were higher than one. This would mean
that there was more phosphorylated Akt than total Akt, which is not possible. Also, the
differences between the non-stimulated and the control stimulated with pervanadate, a
phosphatase inhibitor (Fig. 4.20A) were not statistically significant. On the other hand,
the p-ERK/ERK ratio graphs, all showed ratios smaller than one (Fig. 4.18B, 4.19B and
4.20B). For the stimulation with heat-killed S. aureus the ratios peaked at 1 minute poststimulation, up to around 0.5 and then decreased until the last time point at 60 minutes,
where a slight peak could be observed (Fig. 4.18B). This would mean that at 1 minute
post-stimulation, half of the ERK molecules in PBMCs were activated. In addition, the 1
minute time point is also the only one that showed a significant difference between the
carrier and the transient carrier, being the pERK/ERK ratio higher in the transient carrier
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than in the carrier (Fig. 4.18B). The p-ERK/ERK ratios from PBMCs stimulated with
PGN peaked at 10 minutes post-stimulation, but in this case there is no significant
difference between the ratios from the carrier and the transient carrier. The control
stimulation with pervanadate showed a significant difference between non-stimulated and
stimulated cells, confirming that ERK is only phosphorylated when cells are stimulated
(Fig. 4.20B).
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Figure 4.18: p-Akt/Akt and pERK/ERK ratios in PBMCs from a carrier and
a transient carrier upon stimulation with heat-killed S. aureus.
PBMCs from a carrier (donor #7) and a transient carrier (donor #11) were
stimulated with 6.25x106 per million cells of heat-killed S. aureus CFUs. Cells were
lysed and p-Akt, total Akt (A), p-ERK and total ERK (B) were measured by ELISA. ***
p < 0.001.
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Figure 4.19: p-Akt/Akt and pERK/ERK ratios in PBMCs from a carrier and
a transient carrier upon stimulation with PGN.
PBMCs from a carrier (donor #7) and a transient carrier (donor #11) were
stimulated with PGN. Cells were lysed and p-Akt, total Akt (A), p-ERK and total ERK
(B) were measured by ELISA.

80

A

pAkt/Akt

OD 450 ratio

1.00

carrier
transient carrier

0.75
0.50
0.25
0.00

-

+

Pervanadate

B

p-ERK/ERK (PGN)
***

OD 450 ratio

0.3

carrier
transient carrier

0.2

0.1

0.0

-

+

Pervanadate

Figure 4.20: p-Akt/Akt and pERK/ERK ratios in PBMCs from a carrier and
a transient carrier upon stimulation with pervanadate.
PBMCs from a carrier (donor #7) and a transient carrier (donor #11) were
stimulated with 1mM pervanadate. Cells were lysed and p-Akt, total Akt (A), p-ERK and
total ERK (B) were measured by ELISA. *** p < 0.001.
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Chapter 5

5

Discussion
S. aureus is not only an important health threat, but also a commensal

microorganism. Infection by S. aureus can lead to life-threatening clinical conditions
such as pneumonia and TSS.3 However it is found in the nostrils of up to 50% of the
general population without causing disease, and carrying these bacteria in the nostrils
leads to a three times higher risk of developing an infection than not carrying it.3 The
immune system recognizes these bacteria through innate immune receptors such as TLR2
and NOD2, which trigger a cytokine response upon ligand binding.43 This immune
response varies according to the cell type that is being stimulated. Monocyte-derived
macrophages produce IL-10, which requires PI3K activity, but monocyte-derived
dendritic cells produce IL-10 and IL-12/23p40.5 This differential response may have
important clinical consequences because macrophages are the main APC found in the
mucosa, including the nasal mucosa, whereas dendritic cells are the main APC in skin
and connective tissues.39 Therefore an immunomodulatory or a pro-inflammatory
immune response to S. aureus would be triggered depending on where the immune
system encounters S. aureus, and which APC is found on site. The results presented in
this thesis were addressing the following hypothesis: the presence of S. aureus in the
nostrils of healthy subjects is due to a predominantly IL-10 immunomodulatory response
driven by the macrophages of the nasal mucosa. Moreover, we predicted that the control
non-carriers group should produce less IL-10 in comparison to carriers, and this
differential IL-10 production should correlate with a differential PI3K activity.
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5.1
5.1.1

S. aureus nasal carriage cohort
Criteria for the assignment of carriage status

To examine the mechanistic implications of the hypothesized differential IL-10
response to S. aureus and how it may determine the persistence of S. aureus in the
nostrils, a cohort of S. aureus nasal carriers and non-carriers was generated over a 16
month period. Subjects were tested for S. aureus presence in their nostrils between one
and five times. The result of the first swab determined the carriage status that was
assigned to each subject, and it did not change unless subsequent swabs provided a
different result. In this case, the subject was considered a transient carrier. However, our
criteria of what constituted permanent nasal carriage, transient carriage and non-carriage
of S. aureus is not the only one, and it differed from that employed in other studies found
in the literature. One study proposed that two swabs within a one week interval,
combined with quantitative considerations (over 105 CFUs to be considered permanent
carrier), should be sufficient to determine nasal carriage.12 In contrast another study
claimed that at least seven nasal swabs were needed to set apart transient carriers and
non-carriers, but quantitative measurements were not necessary.3 For the generation of
the cohort for the research presented in this thesis, quantitative differences in S. aureus
bacterial load found in the swab, to determine carriage status was not taken into
consideration, nor was fixed frequency of the swabs performed. Together, this
methodology could lead to an underestimation of transient carriage numbers, since the
more swabs that are analyzed from a given subject, the higher the probability they will be
classified as a transient carrier.3
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5.1.2

Carriage rates
Our study cohort was comprised of 14% carriers, 5% transient carriers and 81%

non-carriers. These numbers differed from to published data, which describes permanent
carriage approximately in 20%, transient carriage around 30% and non-carriers make up
50% of the population. However our permanent carriage rates were still within the range
of previous observations of between 12% and 30%.3 The percentages obtained in the
cohort presented in this thesis were in the lower range, likely due to the small sample size
of 126 subjects. Many recent studies have focused on patients for a variety of diseases
from HIV infection to renal failure, and cohorts studying these population groups range
in size from less than 100 to over 700 subjects.89 Cohorts comprised of healthy subjects
showed the greatest variation on their size, ranging from just over 50 subjects90,
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to

nearly 4000 subjects.92 The size of our cohort is within the range of previously published
data, but it is still small. Evidently, the bigger the size of the cohort, the better it
represents the overall population. The low percentage of permanent carriers, and transient
carriers in particular, in the cohort presented here, was probably also due to the low
number of swabs obtained from the same subjects. Even though some subjects of the
cohort were swabbed several times, most of them were swabbed just once or twice. This,
as explained above, reduced the chance of successfully identifying transient carriers, and
not only explains the low percentage of transient carriers found in the cohort, but also the
high percentage of non-carriers. Differences in culture techniques have also been reported
as a potential factor in the efficiency of identifying S. aureus in nasal swabs.26
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Several subjects in the cohort, such as transient carrier subject #11, tested
negative for S. aureus in their nasal swabs several time throughout the length of the
study, but towards the end they tested positive. These subjects were switched from the
non-carriers group to the transient carriers group, and data from them was treated as such.
There are some studies that consider a fourth category: occasional carriers,3 but this
alternative carriage status was not considered in the research presented here due to the
low frequency of swabbing for each subject.

5.1.3

Demographics of the cohort
A gender and age profile analysis of the cohort was carried out. The majority

(83%) of the subjects in the cohort, which was mainly formed by students and fellow
researchers, were between 18 and 39 y, with an average of 22.2 y. According to the
literature, those at a younger age exhibit a higher rate of S. aureus nasal carriage,3 but this
was not the case in the cohort presented here. In fact, there is a trend for the opposite
since 33% of the carriers were 40 y or older, as opposed to 15% of the non-carriers.
However, these differences between the carriers and the non-carriers groups in the
number of subjects who were 40 y or older were not statistically significant. The
discrepancy between the observations reported in the literature and the percentages found
in this cohort are likely due to the small number of subjects included in our studies,
especially for subjects 40 y and older.
The study presented in this thesis was mainly focused on the differences between
carriers and non-carriers. These two groups had a similar age distribution within their
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components (carriers: 33% of subjects 40 years age or older, average of 24.2 years; noncarriers: 15% of subjects 40 years age or older, average of 21.9 years). The number of
times that subjects in these groups were swabbed was also similar. Therefore, the
different responses studied in this thesis from these subjects cannot be explained by
differences in age, gender or number of swabs taken (reliability of the carriage status
assigned to each subject). S. aureus nasal carriage status would be their only known
difference.
Regarding gender distribution in the cohort, the male and female rates are not
only similar in the overall cohort, but also within the different groups. However, previous
studies have found higher carriage rates in males than females.3, 12, 26 This was thought to
be a potential prediction factor for S. aureus carriage in a clinical setting where surgery
was needed. Nevertheless, not enough statistical evidence has been found to consider
gender a prediction factor for S. aureus nasal carriage, nor has an explanation for this
observation been proposed yet.93
Conversely, age, gender, ethnicity and genetic differences have not been
controlled for in this study, and therefore they cannot be dismissed as factors that might
play a role when analyzing the differences in responses between carriers and non-carriers.
Nasal carriage rates have been reported to be higher among Caucasians27 and there is
evidence that the host factor could play a key role in determining the carriage status of a
given subject.19 Taking all of these factors into consideration, the impact of genetic
differences might contribute to different ways of responding to S. aureus among subjects,
and have a critical role in determining nasal carriage status. These genetic differences
could correlate with ethnic differences. Several SNPs in the IL10 gene have been
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associated with sepsis94 and septic shock,95 chronic hepatitis C,96 severe malarial
anemia97 and HIV pathogenesis.98

5.2

S. aureus nasal isolates

Any S. aureus strain can become a life-threatening pathogen, but some strains are
more virulent than others. Differences in virulence are determined by the genome and can
lead to different efficiencies of colonization.12 The different isolates from the carriers in
the cohort presented here have not been genotyped; therefore their degree of genetic
relatedness is unknown and could be assessed in future studies. It is possible that they are
not very different because they were isolated from subjects residing in the same
community. MRSA carriage rates among children have been linked to sustained
transmission and colonization within the community,13 and some bacterial clones are
more common than others within a population.20 Therefore, it might be more likely that
S. aureus strains genetically closer are found circulating within a given community, than
in two separated communities. Nevertheless, this hypothesis must be tested formerly
since it was also shown that the same S. aureus genotypes can be found among the
American and the Dutch communities.99
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5.3
5.3.1

Cytokine responses
Study subjects

The selection of subjects in the cohort for further studies was based on their S.
aureus carriage status and their availability for blood donation. Even though ideally the
cytokine responses from all the members in the cohort should have been measured, the
number of subjects for which blood work was routinely available was very low due to
high dropout rates. Previous studies that measured IL-10 in plasma ranged greatly in the
number of subjects included in each study, from 10 subjects to over 3000 subjects.96, 100
The demographic profiles of the selected subjects from our cohort were representative of
each of their specific carriage status groups, and of the overall cohort in terms of gender
and age distribution.

5.3.2

PBMCs as a model for macrophages in the nasal
submucosa
The major reservoir of S. aureus in the human body is the anterior nares,3 where

macrophages are the main APC.6 Due to the difficulty of getting access to submucosal
tissue from this area of the body, PBMCs were used as a model for the immune response
taking place in the nostrils. PBMCs are a mixed population of different immune cells
such as T cells, B cells, NK cells, dendritic cells, and monocytes.6 As all the experiments
were performed using PBMCs, the responses observed do not represent how a specific
cell type responds to heat-killed S. aureus or PGN, but the combination of all the
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responses from all the different cell types in PBMCs. Furthermore, the responses from a
given cell type could affect how other cell types respond to heat-killed S. aureus or PGN,
and potentially bias the results obtained in this research with respect to IL-10 and TNF-α
production, and Akt and ERK phosphorylation. Other research studies have used a cell
line derived from human nasal epithelial cells.101 However, even though these cells are
isolated from the site of colonization and can produce cytokines in response to S. aureus,
they are not professional APCs. More importantly, it is not known whether the cell line
was derived from a carrier or a non-carrier. With respect to the model used for the
research presented in this thesis, PBMCs were isolated from the same subjects in the
cohort whose carriage status had been pre-determined and were exposed to the same
isolate that was found in their nostrils, or to other commensal isolates. Even though
PBMCs were not equivalent to the macrophages found in the nasal submucosa, they can
still provide information on whether there is a difference between the immune responses
from S. aureus carriers and non-carriers and what additional variables may be introduced
in the process of generating these lines.

5.3.3

Cytokine responses to heat-killed S. aureus
No differences in the IL-10 response by PBMCs from carriers to their autologous

isolate and to heterologous isolates were observed. Moreover, PBMCs from non-carriers
also showed similar responses to all the isolates that they were exposed to (data not
shown). Therefore, stimulation of PBMCs with different S. aureus isolates did not cause
a differential IL-10 response among any of the carriage groups.
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The cytokine responses from carriers exposed to their autologous S. aureus nasal
isolate and non-carriers to those same isolates were not significantly different in this
study. However, there was a trend for the carriers’ IL-10 response to be higher than the
IL-10 response of the non-carriers, and the IL-10 responses from carriers exposed to
heterologous isolates were significantly higher than those from non-carriers. Although
statistical significance was only reached at one of the concentrations of heat-killed S.
aureus CFU tested, the trend for the IL-10 response to be higher in the carriers group
than in the non-carriers might reflect biological significance. This suggests that IL-10
production might not be divided into two differentiated levels of production, but rather
that inter-individual variation results in a range of IL-10 production. In this case, the
carriers group would tend to be within a higher range of IL-10 production, while the noncarriers will exhibit a lower range of IL-10 production. However, these two ranges may
still overlap taking all the subjects together. Consequently, even though it would be hard
to reach statistical significance between the two carriage groups, the trend for differential
IL-10 production would still have biological significance. These observations suggest
that a higher IL-10 production might be associated with S. aureus nasal carriage and a
lower IL-10 production with S. aureus nasal non-carriage. Taking into consideration that
exposure of PBMCs from a same given subject to different S. aureus nasal isolates did
not cause a differential IL-10 response, the results suggest that the differential IL-10
production might not be caused by different isolates, but by differences in host factors,
such as higher IL-10 production. This differential IL-10 production might be playing a
primary role in allowing for commensalism and as a result, determining the carriage
status of an individual. If this result could be confirmed by increasing the number of
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subjects, it would be in agreement with previous observations.19 Nevertheless, and as it
was stated above, the genetic relatedness of the different isolates in our study was
unknown, and therefore we cannot exclude the possibility that the similarities observed
for the immune responses from carriers exposed to autologous and heterologous isolates
were just due to genetic similarity among all the isolates.
TNF-α production in response to heat-killed S. aureus was also analyzed. There
was no difference in the TNF-α responses by PBMCs from carriers exposed to
autologous isolates, carriers exposed to heterologous isolates, or from non-carriers. The
IL-10 and TNF-α profiles analyzed together suggest that carrying S. aureus in the nostrils
cannot be a consequence of a lack of a pro-inflammatory response, but rather a
consequence of an immune response dominated by another immunomodulator such as
IL-10. It has been shown that macrophages produce IL-10, but not IL-12/23p40, in
response to PGN and LTA, as opposed to dendritic cells, which produce both.5 In this
thesis, TNF-α production was used as a measure of pro-inflammatory cytokines
production, instead of IL-12/12p40, which is also pro-inflammatory.39 A possible
mechanism that explains the presence of S. aureus in the nostrils of some subjects
without causing disease is that macrophages in the submucosa represent a specific cell
type that produce predominantly IL-10 in response to S. aureus cell wall products. It is
well established that IL-10 can down-regulate a pro-inflammatory immune response.60 As
a consequence, bacteria are allowed to persist in the nostrils but not allowed to invade
any other tissue either. IL-10 would also down-regulate the IL-2 response from T cells
activated by superantigens secreted by S. aureus.4 This possible mechanism would also
explain the outcome of S. aureus infections at skin lesions, since the main APC found in
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the dermis are dendritic cells, and they do not produce IL-10 in response to
staphylococcal ligands. Therefore, only a pro-inflammatory response would be mounted
against the infectious agent, and it would be more likely to be aggravated by the
consequences of a cytokine storm induced from super antigen-activated T cells.11
PBMCs from transient carriers exposed to heterologous isolates exhibited a dose
response very similar to the ones from carriers and non-carriers, for both IL-10 and TNFα production, i.e. IL-10 production peaked at 1.25x107 CFU and TNF-α production
reached a plateau at the higher CFU values. Although the dose responses results from
transient carriers were similar, they did not seem to follow a trend when compared to the
other two groups, and the differences were not statistically significant either. Increasing
the number of transient carriers might help to define a more specific profile in their
cytokine responses to S. aureus. Due to the difficulty in identifying transient carriers in
the cohort employed in this study presented here, the number of subjects used for these
experiments was lower than the number of carriers and non-carriers. Differentiating
between permanent and transient carriers has clinical consequences. Patients on chronic
ambulatory peritoneal dialysis who are permanent carriers are at risk of becoming autoinfected, whereas the incidence for transient carriers is similar to that of non-carriers.3

5.3.4

Cytokine responses to PGN
Because the previous experiments were performed using heat-killed S. aureus, it

led us to think that the bacterial ligands that were triggering the cytokine response could
be located in the staphylococcal cell wall, which is mainly composed of PGN1 and has
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TLR2 ligands embedded in it.4 To examine if stimulation with PGN could recapitulate
the same cytokine responses in PBMCs seen upon stimulation with heat-killed S. aureus,
similar experiments to the ones performed with the bacteria were repeated, but PGN was
used as the stimulant instead. The IL-10 responses by PBMCs from carriers and noncarriers to PGN are very similar to the IL-10 responses by PBMCs from these groups to
heat-killed S. aureus. Even though the IL-10 dose response to PGN and heat-killed S.
aureus were very similar, stimulation with PGN alone did not recapitulate the differential
IL-10 response between carriers and non-carriers. This could be due to: (1) the higher
variability within IL-10 levels in response to PGN, which leads to higher standard error
values, and/or (2) a lower number of subjects used for the PGN experiments (N
carriers=7, N non-carriers=5) than for the experiments with heat-killed S. aureus (N
carriers=9, N non-carriers=10). The TNF-α dose response to PGN by PBMCs from
carriers and non-carriers differed from the TNF-α dose responses to heat-killed S. aureus
by PBMCs from the same carriage groups. The TNF-α dose responses to PGN increased
across the PGN concentration range tested, whereas TNF-α dose responses to heat-killed
S. aureus reached a plateau on the higher CFU values. This difference could again be due
to the different number of subjects used for the two different stimulants.
The TLR2 ligands that trigger the IL-10 response in PBMCs are embedded in the
staphylococcal PGN;5 therefore they are present in both stimulants: heat-killed S. aureus
and staphylococcal PGN.

Because of this localization of the TLR2 ligands in the

bacteria, one would expect that this PGN would trigger a similar response to that
triggered by the whole bacteria. Nevertheless differences in the observed responses might
be explained by differences in the accessibility of these ligands to their receptors. The
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lipopeptides and glycopolymers in the PGN are probably more accessible to TLR2
molecules on the cell surface and that may lead to faster signal transduction starting
before PGN is internalized, whereas stimulation with heat-killed S. aureus requires
internalization and degradation of the bacteria into the phagolysosome in order for PGN
ligands to be made accessible to TLR2 molecules.79
In addition, all the PGN used for these experiments was purchased and came from
the same S. aureus strain. Therefore, experiments should be repeated using PGN from
genetically distinct S. aureus strains. If genetic differences among S. aureus strains can
lead to differences in virulence,12 future research could study if these genetic differences
can also affect the lipopeptide and glycopolymer composition of staphylococcal PGN.

5.4
5.4.1

Akt and ERK activation in response to S. aureus
Western blotting

Since there is a trend for the IL-10 response to heat-killed S. aureus by PBMCs
from carriers to be higher than the one by PBMCs from non-carriers, and because PI3K
activity is required for IL-10 production,5 it was necessary to test if this trend for a
differential IL-10 response correlated with a differential PI3K activity. Akt
phosphorylation, and consequent activation, is a commonly used method to asses PI3K
activity.5 Western blotting results show that Akt and ERK, which is also activated upon
TLR2 ligation,43 are phosphorylated upon heat-killed S. aureus and PGN stimulation,
which is in agreement with previous reports.5, 43 However, it is not possible to conclude
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whether this phosphorylation is different between carriers and non-carriers because the
protein concentration loaded across the lanes did not appear to be equal, which can be
observed in the corresponding total Akt, total ERK and GAPDH (protein loading control)
blots. Taking into consideration previous observations that IL-10 production is dependent
on PI3K activity,5 and that PBMCs from carriers tended to produce higher IL-10 than
PBMCs from non-carriers, one would expect to see higher Akt phosphorylation in
PBMCs from carriers than from non-carriers. However, to reach this conclusion, equal
protein concentration across all the samples of the time course would be necessary.
Although these experiments suffered from a number of limitations, including unequal
loading, or possibly unequal protein transfer, it was nevertheless observed that Akt and
ERK were activated in a time dependent manner, with a peak around 1 and 5 minutes
post-stimulation with heat-killed S. aureus, for both the carrier and the non-carrier. The
carrier (subject #8) and the non-carrier (subject #22) had both been swabbed 4 times, and
there is no statistically significant difference between their IL-10 responses, which could
explain the observation of similar phosphorylation levels of Akt between the two but the
current data is inconclusive. However, the data did show that there was a difference in the
minimum number of heat-killed S. aureus CFUs required to trigger an IL-10 response:
PBMCs from subject #22 start producing IL-10 at lower CFU levels than PBMCs from
subject #8.

5.4.2

ELISA analysis of phospho-proteins
In addition to western blotting, phosphorylation of Akt and ERK was also tested
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using ELISA, which allows for accurate quantification. Unfortunately, the subject used
for ELISA experiments that was supposed to be a non-carrier was found to be a transient
carrier. Therefore, the results from these experiments cannot be used to test differences
between S. aureus carriers and non-carriers, but instead between carriers and transient
carriers. However, this is a mute point since the Akt results were inconclusive because
the p-Akt/Akt ratios were higher than 1. This implies that there would be more
phosphorylated Akt than total Akt in the cell lysates. As this situation is not possible, the
results suggest the need for further optimization of the protocol. It is possible that the
protocol as it is, is giving too much background signal. This can be seen in the difference
between the p-Akt/total Akt ratios from non-stimulated and pervanadate-stimulated cells,
which was not significant. On the other hand, p-ERK/total ERK ratios remained below
one for all the stimulations. The p-ERK/total ERK ratio is higher in the transient carrier
than in the carrier at the 1 minute S. aureus stimulation time point. Subjects whose data
were used in this experiment had been swabbed 4 times for the carrier (subject #7) and 5
times for the transient carrier (subject #11). It is possible that the carrier is actually a
transient carrier. In this case the difference in ERK phosphorylation would simply be a
consequence of biological inter-individual variation in the response. However, because
this experiment was only performed once and with PBMCs from one subject
representative of each group, it is not possible to draw a conclusion about how these cells
behave in every carrier or transient carrier in the population. This experiment would have
to be repeated to confirm this preliminary observation of higher phosphorylation of ERK
in PBMCs from transient carriers than from carriers exposed to heat-killed S. aureus.
Activation of ERK leads to activation of the FBJ murine osteosarcoma viral oncogene

96

homolog (Fos) transcription factor, which activates transcription of IL-23p19.46 Thus
analyzing production of this cytokine subunit could provide additional information. The
IL-10 responses from both subjects did not show statistically significant differences.
Interestingly, it was the various IL-10 responses from the transient carrier (subject #11)
that did show statistically significant differences. When subject #11 tested negative for
presence of S. aureus in the nostrils, IL-10 responses tended to peak at 1.25x108 CFUs,
whereas the IL-10 response obtained from when he was identified as a transient carrier
peaked at 1.25x107 CFU. Even though it could be argued that the presence of the bacteria
in the nostrils has an effect on the responses of PBMCs in vitro, the lack of any
repetitions for these specific conditions does not allow one to reach a valid conclusion.

5.5

Conclusions and future avenues

In conclusion, the cohort generated in this study, which compared responses from
S. aureus nasal carriers to non-carriers is representative mainly of subjects younger than
40 y. Of interest, we found that the percentages of carriage are lower than the average
reported, but still within the range reported in the literature (12%).3 Nevertheless, the
percentage of transient carriage is very low and probably underestimated due to the low
number and frequency of swabbing among the subjects in the cohort.
For future directions in the research presented here, one possibility is to swab
each subject in the cohort up to seven3 times before assigning them to a carriage status
group. It would also be very beneficial to increase the size of the cohort to a total of 200 –
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400 subjects, considering previous published data.89-91 These two measures would
provide more robustness to the cytokine production profiles of the different carriage
groups, which need to include more subjects as well. Obtaining quantitative cytokine
production profiles, especially for IL-10, from all the subjects from a cohort of increased
size would be ideal.
Previous studies that have examined IL-10 in plasma have also showed
associations between several single nucleotide polymorphisms (SNPs) on the IL10 gene
and IL-10 plasma levels.96,
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It would be of great interest to further explore these

observations and study a potential association between the different IL10 gene SNP
variants and the carriage status of the subjects in the cohort presented here.
In addition, it would increase the clinical relevance of the project to have access
to nasal submucosal tissue from subjects whose carriage status has been determined, and
repeat the stimulations presented in this thesis with macrophages isolated from such
tissue. Obtaining nasal mucosal tissue from subjects that have suffered an active S.
aureus infection would also provide valuable information about the differences between
subjects that remain healthy and subjects that develop disease. Using these samples to test
IL-10 production and its correlation with PI3K/Akt activity would further confirm the
importance between commensal nasal carriage and IL-10-mediated immunomodulation.
Finally, genotyping the S. aureus isolates used in the stimulation of PBMC
cultures would provide a more complete understanding of what may underlie the
observed differences in the IL-10 responses between subjects in a given carriage status
group and between the different groups. Also, testing the IL-10 response with respect to
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genotypically different isolates obtained from subjects with S. aureus disease would
provide significant insight into answering the question of what drives the different
outcomes of an interaction between S. aureus and a human host.
The data presented in this thesis are consistent with previous studies that suggest
host factors to be critical in determining the nasal carriage status of a given subject.
Further experiments are required with a larger number of subjects to confirm that carriers
produce more IL-10 than non-carriers when exposed to heat-killed S. aureus as an early
preliminary conclusion. S. aureus nasal carriage has been shown to be a risk factor for S.
aureus infection, which can lead to life-threatening disease. Understanding the
mechanism that allows for these bacteria to persist in the nostrils of healthy subjects will
help to generate better strategies to deal with it not only at the community level, but also
at the health-care level, where it is especially dangerous. Elucidating this mechanism
would also provide valuable information about the balance between the immune
responses to S. aureus and its ability to cause disease or remain as a commensal.
Understanding this dichotomy of S. aureus-host interactions could be a key factor in
developing efficient treatments or preventive measures.
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Appendix B

Heat-killed S. aureus stimulation.
Membrane blotted for p-Akt, total
Akt and GAPDH.

PGN stimulation. Membrane
blotted for p-Akt, total Akt and
GAPDH.

Heat-killed S. aureus stimulation.
Membrane blotted for p-ERK, total
ERK and GAPDH.

PGN stimulation. Membrane
blotted for p-ERK, total ERK
and GAPDH.

Pictures of gels stained with Coomassie blue after transfer.
Representative images of Commassie blue-stained gels after transfer. In this case,
samples from PMBCs from subject #8 and subject #22 (corresponding to Fig. 4.9 and
4.12) were subjected to SDS-PAGE and transfer to PVDF membranes. Following transfer
the SDS-PAGE gels were stained with Coomassie blue. A description the stimulant used
for each sample that was run, as well as the western blot analysis of the membranes
corresponding to each gel is presented beneath each gel image.
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